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MONOCLONAL ANTIBODY PRODUCTION AGAINST HEPATITIS B 
CORE ANTIGEN 
 
SUMMARY 
Hepatitis B is a disease of the liver caused by the Hepatitis B virus (HBV), which is a 
member of the Hepadnaviridae (Hepa = liver; dna =  deoxyribonucleic acid)  family. 
Hepatitis B virus is one of the major cause of acute and chronic hepatitis, cirrhosis 
and hepatocellular carcinoma. It is a serious global public health problem, as 
Hepatitis B is largely transmitted by the exchange of body fluids such as blood, 
breast milk and in some circumstances saliva. People most at risk include antibody 
who has unprotected sexual intercourse, drug users who share needles and syringes, 
health care workers in contact with potentially contaminated blood or body fluids, 
anyone in intimate contact with the infected person.  
Hepatitis B virus is very common in Asia, Philippines, China, Africa and the Middle 
East. In these regions, liver cancer caused by HBV figures is among the first three 
causes death by cancer in men. It is estimated that there are 280 million Hepatitis B 
carriers worldwide representing more than 5% of the global population.  
In Turkey, approximately there are 3-4 million carriers according to “Communicable 
Disease Department Ministry of Health Turkey”. Half of this result is because of 
insufficient detection and pathogen diagnosis. In our country, most of the diagnostic 
kits used for the diagnosis of various human diseases, as well as Hepatitis, are 
imported. The use of imported diagnostic kits causes economical dependency and 
causes important economical losses because of its high cost.  
For this purpose, diagnostic systems based on the use of monoclonal antibodies and 
molecular techniques are planned to be developed for early and sensitive diagnosis of 
Hepatitis B in this project supported by TUBiTAK. Hepatitis B core Antibody 
(HBcAb) is an antibody to the Hepatitis B core antigen (HBcAg). HBcAb is 
 x
considered  to be  a  sensitive and specific serum marker of HBV infection. In some 
patients, HBcAb is the only marker in the absence of Hepatitis B surface antigen or 
Hepatitis B antibody (HBsAg or anti-HBs). 
In my thesis study, the aim is to produce monoclonal antibodies against HBcAg by 
using hybridoma technology in order to use the Hepatitis B diagnostic panel as a 
future aspect. For this purpose, 6-8 weeks old BALB/c mice were immunized with 
hepatitis core antigen. Fusion study was carried out by using Hybridoma Technology 
with the highest immune response giving one among mice. 5 different fusion studies 
were done. In fusion studies, spleen and lymph nodes were used as a B lymphosite 
source. Spleen and lymph node cells were fused in the presence of  
polyethylenglycol. As a last fusion study result, among 1144 wells, 693 hybrid clon 
were obtained and among this clone 1 clone’s antibody product was determined to 
give specific reaction against hepatitis B core antigen.  
Monoclonal antibodies can be used for variety of purposes and one of them is 
identifying infectious agents. For this purpose, Enzyme Linked Immuno Sorbent 
Assay (ELISA) test systems are used. There are numerous kinds of ELISA test 
systems that can be used to identify infectious agents in serum. In this study, 
monoclonal antibodies against HBcAg will be produced in mice and as a future 
aspects it will be used in competitive sandwich ELISA test systems. On the other 
hand, rabbits are immunized with the same antigen for production of polyclonal 
antibodies and the products will be used in capture ELISA test systems for detecting 
HBcAg in the serum.  
Key words:  
Hepatitis B Virus (HBV), HBV Core Antigen, Monoclonal Antibodies, ELISA Test 
Systems, Diagnostic Kits, Hybridoma Technology 
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HEPATİT B KOR ANTİJENİNE KARŞI MONOKLONAL ANTİKOR 
ÜRETİMİ 
ÖZET  
Hepatit B, Hepadnavirüs ailesinden olan hepatit B virüsünün neden olduğu bir 
karaciğer hastalığıdır. Hepatit B virüsü (HBV), akut ve kronik hepatit, karaciğer 
kanseri ve sarılık gibi önemli hastalıkların etkenidir. HBV kan, vücut sıvı ve salgılar 
(süt vb.) yoluyla kolaylıkla bir canlıdan diğerine geçebileceği için halk sağlığı için 
önemli bir sağlık sorunu olmaktadır. Korunmasız seks, ilaç kullanımına bağlı olarak 
enjektör, kan veya vücut sıvısıyla temas halinde olan sağlık çalışanları hepatit B 
hastalığı için risk altındadır. 
Hepatit B virüsü Çin, Asya, Filipinler, Afrika ve Orta Doğu’da oldukça yaygındır.  
Bu bölgelerde HBV’ye bağlı karaciğer kanseri, insanda kansere neden olan ilk üç 
nedenlerin arasındadır. Tüm dünyada yaklaşık 280 milyon kronik HBV taşıyıcısı 
vardır ve her yıl yaklaşık 2 milyon insan HBV ile ilişkili hastalıklar dolayısıyla 
ölmektedir.  
Sağlık Bakanlığı Bulaşıcı Hastalık Departmanı’na göre Türkiye’de yaklaşık olarak 
3–4 milyon Hepatit B taşıyıcısı vardır. Bu sayının yüksek olmasının bir başka nedeni 
ise virüsün yeterli tanı ve teşhisinin yapılamamasıdır. Ülkemizde HBV tanısında 
olduğu gibi, insan sağlığı açısından oldukça önemli olan çeşitli hastalıkların teşhis ve 
araştırma çalışmalarında kullanılan tanı kitlerinin büyük bir kısmı yurt dışından ithal 
edilmektedir. Bu sebeple kitler yüksek fiyatları nedeniyle ekonomik kayıplara neden 
olmaktadır.  
Bu amaçla, monoklonal antikor ve moleküler tekniklere dayanılarak geliştirilecek 
Hepatit B tanı sistemleri TÜBİTAK Projesi çatısı altında yapılacaktır. Hepatit B kor 
antikoru, Hepatit B enfeksiyonunun tanısında duyarlı ve spesifik serum işaretleyicisi 
olarak bilinmektedir. Ayrıca bazı hastalarda Hepatit B kor antikoru, hepatit yüzey 
antijeninin ya da antikorunun yokluğunda tek serum belirleyicisi olarak 
kullanılmaktadır. Tez çalışmamda, Hibridoma tekniği kullanarak Hepatit B kor 
 xii
antijenine karşı monoklonal antikor geliştirip ileriye yönelik olarak geliştirilecek 
antikorların tanı kitlerinde kullanılması yer almaktadır.  
Bu amaçla, deneylerde hepatit B kor antijeni ile 6-8 haftalık BALB/c fareler 
immünize edildi. Hibridoma teknolojisi kullanılarak güçlü antikor yanıtı alınan 
fareler ile füzyon çalışması gerçekleştirildi. 5 ayrı füzyon deneyi yapıldı. 
Füzyonlarda B lenfosit kaynağı olarak dalakla birlikte lenf düğümleri kullanılmıştır. 
Dalak ve lenf düğümü hücreleri fare myeloma hücreleri ile polietilen glikol 
varlığında birleştirilmiştir. Son füzyon çalışması sonucunda 1144 kuyudan 693 hibrit 
klon elde edilmiş ve bu klonlar içerisinde 1 klonun ürettiği antikorun hepatit kor 
antijeni ile özgün reaksiyon verdiği belirlenmiştir. 
Monoklonal antikorlar farklı amaçlarda kullanılabilirler; bunlardan bir tanesi 
serumda enfeksiyöz materyallerin belirlenmesidir. Bu amaçla ELISA test sistemleri 
kullanılmaktadır. Farede geliştirilen monoklonal antikorlar, aynı zamanda 
tavşanlarda üretilen poliklonal antikorlar yarışımlı ELISA tanı sistemini kurmak için  
kullanılacaktır. 
Anahtar Kelimeler:  
Hepatit B Virüsü (HBV), Hepatit B kor antijeni, Monoklonal Antikorlar, ELISA Test 
Sistemleri, Tanı Kitleri, Hibridoma Teknolojisi 
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1. INTRODUCTION 
1.1 Viral Hepatitis 
Viral hepatitis is an infection of the liver that affects people from all age, race, 
gender or sexual orientation. Many viruses can inflame the liver (Fig 1.1). When 
doctors speak of viral hepatitis, they usually are referring to hepatitis caused by a few 
specific viruses that primarily attack the liver. There are several different viruses that 
cause hepatitis. They are named as hepatitis A, B, C, D, and E viruses.  
 
 
 
 
 
 
 
Figure 1.1: Inflammation Types of the Liver [1, 2]. 
1.2 Function of Liver 
The liver is located in the upper right hand side of the abdomen, behind the rib cage. 
The liver performs the following vital functions: 
1. The liver helps purify the blood by changing harmful chemicals into harmless 
chemicals. The source of these chemicals can be external, such as alcohol, or 
internal, such as ammonia or bilirubin. Typically, these harmful chemicals are 
broken down into smaller chemicals or attached to other chemicals that then are 
eliminated from the body in the urine or stool.  
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2. The liver produces many important substances, especially proteins that are     
necessary for good health. For example, it produces albumin, the protein building 
block of the body, as well as the proteins that cause blood to clot properly.  
3. The liver stores many sugars, fats and vitamins until they are needed elsewhere in 
the body.  
4. The liver builds smaller chemicals into larger, more complicated chemicals that 
are needed elsewhere in the body. An example of this type of function is the 
manufacture of cholesterol.  
When the liver is inflamed, it does not perform these functions well, which brings 
about many of the symptoms, signs, and problems associated with hepatitis. 
1.3 Types of Viral Hepatitis 
There are five common types of viral hepatitis, these are A,B,C,D and E hepatitis [3]. 
1.3.1 Hepatitis A 
This type of hepatitis is usually spread by fecal-oral contact or fecal-infected food 
and water, and can be spread by blood-borne infection. The hepatitis caused by 
Hepatitis A Virus (HAV) is an acute illness (acute viral hepatitis), and it does not 
have a chronic stage. Hepatitis A was referred to as "infectious hepatitis" because it 
could be spread from person to another like other viral infections. The patient's 
immune system makes antibodies against Hepatitis A; hence, confers immunity 
against future infection. People with hepatitis A are advised to rest, stay hydrated and 
avoid alcohol. A vaccine is available that will prevent infection from hepatitis A for 
life. Hepatitis A can be spread through personal contact, consumption of seafood or 
drinking contaminated water. This occurs primarily in third world countries. 
1.3.2 Hepatitis B  
Hepatitis B is a viral hepatitis caused by a virus of the Hepadnaviridae family. 
Hepatitis B can cause both acute (self-limited) and chronic (long-standing) hepatitis. 
Persons with acute infection clear the infection spontaneously within weeks to 
months. In chronic infection, it develops in the 15% of patients who are unable to 
eliminate the virus after an initial infection. Identified methods of transmission 
include blood transfusion, sexually through contact with blood or bodily fluids, or in 
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uteri (from mother to her unborn child, as the virus can cross the placenta) [4]. 
Moreover, this virus is able to survive at least seven days outside the body and exist 
in high concentrations on objects even in the absence of visible blood [5]. 
1.3.3 Hepatitis C 
There are about 150,000 new cases of hepatitis C each year. Type C hepatitis was 
previously referred to as "non-A, non-B hepatitis" because the causative virus had 
not been identified, but it was known to be neither hepatitis A nor hepatitis B. The 
hepatitis C virus (HCV) usually is spread by shared needles among drug abusers, 
blood transfusion, hemodialysis, and needle sticks. Transmission of the virus by 
sexual contact is rare. Hepatitis C may lead to a chronic form of hepatitis, 
culminating in cirrhosis. It can remain asymptomatic for 10-20 years. No vaccine is 
available for hepatitis C. The virus, if detected early on, can be treated by a 
combination of interferon and the antiviral drug Ribavirin. 
1.3.4 Hepatitis D 
This form of hepatitis can only occur in the presence of hepatitis B. Hepatitis D can 
occur at the same time as the initial infection with B, or it may show up much later. 
Transmission of hepatitis D occurs the same way as hepatitis B, except the 
transmission from mother to baby is less common. 
1.3.5 Hepatitis E 
This form of hepatitis is similar to hepatitis A. Transmission occurs through fecal-
oral contamination. It is less common than hepatitis A. Hepatitis E is most common 
in poorly developed countries. There is no vaccine for hepatitis E at this time. 
1.4 History of Viral Hepatitis 
3 Early Mesopotamian civilizations thought that the liver was the basis of life. They 
were therefore familiar with liver disease and jaundice (the yellow discoloring of the 
skin and eyes that is a common symptom of hepatitis B infection).  
3 By 1885, it was known that hepatitis could be transmitted by syringes and blood 
transfusions.  
3 By 1947, the terms hepatitis A and hepatitis B had been coined by MacCullum to 
distinguish among a number of outbreaks in the late 1930's. 
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3 Between the late 1950's and 1970's, Murray had demonstrated that hepatitis 
disease could be transmitted orally.  
3 In 1963, Baruch Blumberg, at the National Institutes of Health and currently at the 
Fox Chase Cancer Center, was examining thousands of blood samples in search of 
inherited polymorphisms among different parts of the world. During this 
investigation, Blumberg discovered that a sample from an Australian aborigine 
contained an antigen, which he later called “Australia Antigen” and is now called the 
Hepatitis B surface antigen, which reacted with an antibody in the serum from a 
hemophiliac subject [6]. 
3 By 1968, Prince and Okochi had determined that the Australia antigen was found 
exclusively in the hepatitis B patients. The characterization of the Hepatitis B surface 
antigen was a milestone in research because it allowed further study despite inability 
to isolate the virus.  
3 In 1981, the first vaccine against hepatitis B called Heptavax was licensed. 
1.5 Classification of Hepatitis Virus 
The Hepadnaviridae family of viruses consists of 5 types of viruses these are:  
Human virus: Hepatitis B Virus 
Animal viruses: Woodchuck hepatitis virus (WHV), Ground Squirrel hepatitis virus 
(GSHV), Peking Duck hepatitis virus (DHBV) (Table 1.1). 
Table  1.1: Main genome characteristics of the different members of the Hepadnaviridae [7]. 
  HBV WHV GSHV DHBV 
Approx. 
genome size 
(kb) 
3.2 3.3 3.3 3.0 
Host Humans, 
primates 
Woodchucks Ground squirrels, 
woodchucks, 
chipmunks 
Ducks, 
geese 
Num. of 
surface 
proteins 
3 3 3 2 
Gene S,C,P,X S,C,P,X S,C,P,X S,C,P 
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Hepadnaviridae family’s viruses are classified together for the following reasons: 
1. They are all enveloped. 
2. They all contain polymerases that can repair the viral DNA genome during 
replication. 
3. They produce lipoproteins containing envelope proteins. 
4. They infect species that are closely related to their natural hosts. 
5. They can produce chronic infections in liver cells. 
Some human diseases associated with the Hepadnaviridae family, these diseases are: 
Acute Hepatitis: Inflammation of the liver which occurs rapidly to damage. 
Chronic Hepatitis: Active, ongoing inflammation of the liver persisting for more 
than six months. 
Cirrhosis of Liver: Cirrhosis is a consequence of chronic liver disease characterized 
by replacement of liver tissue by fibrotic scar tissue as well as regenerative nodules, 
leading to progressive loss of liver function. The hepatitis B virus is probably the 
most common cause of cirrhosis worldwide. 
HepatoCellular Carcinoma (HCC): Hepatocellular Carsinoma develops when 
there is a mutation in the cellular machinery that causes the cell to replicate at a 
higher rate or results in the cell avoiding apoptosis. In particular, chronic infections 
of Hepatitis B can aid the development of hepatocellular carcinoma by repeatedly 
causing the body's own immune system to attack the liver cells. Hepatitis B carriers 
have a 300 times greater risk of developing this cancer than uninfected individuals. 
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 2. HEPATITIS B 
HBV is a virus of Hepadnaviridae that is pathogenic to man.  As their name implies, 
all of the known hepadnaviruses are hepatotropic, infecting liver cells, and all can 
cause hepatitis in their known host. Hepatitis is a syndrome characterized by 
inflammation of the liver. It can be caused by hepatitis viruses (not necessarily in the 
Hepadnavirus family), other viruses like cytomegalovirus, Epstein-Barr virus, yellow 
fever and non-infectious agents such as alcohol.  
Hepatitis B is the most common serious liver infection in the world, and it is 100 
times more infectious than the AIDS virus. HBV is the most efficiently transmitted 
through contact with blood and body fluids of an infected person. This can occur 
through direct blood-to-blood contact, sex, illicit drug use, and from an infected 
mother to her newborn during delivery. HBV spreads because many people are 
unaware that they are infected with the virus and unknowingly pass it onto those who 
are in close contact with them. 
2.1 Epidemiology of Hepatitis B  
Hepatitis B is one of the major diseases of humankind and is a serious global public 
health problem. Most people are able to fight off an HBV infection and clear the 
virus from their blood. However, 5-10% of adults, 30-50% of children, and 90% of 
infants will develop chronic infection that can lead to liver failure, cirrhosis or cancer 
of the liver. Approximately 400 million persons worldwide are chronically infected 
with HBV.  
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Hepatitis B is endemic in most of Africa, central and Southeast Asia, equatorial 
region (Fig 2.1). 
 
 
 
 
 
 
Figure 2.1: Colored Geographic Risk Distribution of Chronic HBV Infection [8]. 
This virus is preventable with safe and effective vaccines that have been available 
since 1982. Although the vaccine will not cure chronic hepatitis, it is 95% effective 
in preventing chronic infections from developing, and is the first vaccine against a 
major human cancer. In 1991, the World Health Organization called for all children 
to receive the hepatitis B vaccine, and 116 countries have added this vaccine to their 
routine immunization programmes.  
In Turkey, almost 1/3 of Turkish population has already infected by Hepatitis B 
virus. Approximately, there are 3-4 million carriers in Turkey according to 
“Communicable Disease Department Ministry of Health Turkey” (Fig 2.2). 
 
 
 
 
 
 
 
 
Figure 2.2: Hepatitis B cases by age in Turkey (1998–2003). 
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2.2 Properties of Hepatitis B Virus 
2.2.1 Structure of HBV 
Human hepatitis B virus is the prototype virus of the hepadnavirus family. 
Observation using the electron microscope reveals three particle types of viral 
Hepatitis B. The first viral particle is 42 nm in diameter, which is called Dane 
particle that is an infectious partical of the virus. Second one is the noninfectious 
quasi-spherical particles which are 20 nm in diameter, and the last one is tubules 
(filamentous) which are approximately 22 nm in diameter (Fig:2.3). 
 
 
Figure 2.3: Electron micrograph of serum containing hepatitis B virus after negative staining, small 
quasi-spherical particles 20 to 22 nm in diameter; tubular forms; and 42nm double-shelled virus.  
(Copyright Dr Linda M Stannard, University of Cape Town, South Africa, 1995) 
The most abundant are small, spherical, noninfectious particles containing surface 
proteins. Tubuler forms of various lenghts, but with a diameter comparable to that of 
the small particles are also observed. On the other hand, Dane particles are covered 
with envelope proteins and contain a nucleocapsid. In the nucleocapsid, there is an 
incomplete double-stranded DNA and a DNA polymerase. On the surface of these 
particals, there are three kinds of envelope proteins. The first one is the small protein 
(SHBs) which is composed of the S region, the large protein (LHBs) contains pre-S1, 
pre-S2, and S domains, and the middle protein (MHBs) contains the pre-S2 and S 
regions. The SHBs is the most common form of these proteins; the percentage of the 
middle protein is 5%–15% and that of the large protein is only 1%–2% (Fig 2.4) [9]. 
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Figure 2.4: Structure of HBV Dane particle [11]. 
22 nm particles are also found in the blood stream of patients infected with HBV. 
These small particles consist of SHB alone or SHB and MHB [10], but do not 
contain LHB. Sometimes, tubular particles with a diameter of 22 nm are also 
observed, which are composed of SHB, MHB, and some LHB. The small particles 
and tubular particles are "empty" envelopes that carry no core proteins or nucleic 
acids.  
The roles and the functional relationships of SHB, MHB, and LHB in particle 
formation are not yet understood. Since SHB is the major component of the small 
particles and the envelope of Dane particles, it is likely to play a dominant role in 
particle formation in association with biological membranes [11,9], but the latest 
observations strongly suggest that in the absence of LHB or MHB, virions carrying 
DNA cannot be formed or else their formation is reduced to a nondetectable level 
[12]. 
2.2.2 Genome of HBV 
HBV virion DNA is a circular, partially duplex molecule of 3.2 kb, whose circularity 
is maintained by 5’ cohesive ends [13]. One of these strands is termed as long          
(L-negative) strand which has terminal protein covalently linked to its 5’end.  
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The other strand is short (S-positive) strand which has a capped oligoribonucleotide 
at its 5’ end. Short strand has a gap region that can be repaired by a virion associated 
polymerase and generate fully duplex genome.  
The position of the 5’ ends of both strands map to regions of short (11 nucleotide) 
direct repeats (DR1) in viral DNA. The 5’ end of the negative strand DNA maps 
within the DR1 while positive strand DNA starts with DR2. These repeats involved 
in priming the synthesis of their respective DNA strands [14]. 
Negative strand DNA is the template for the synthesis of the viral mRNA transcripts. 
HBV DNA has very compact coding organization with four partially overlapping 
open reading frames (ORFs) that are translated to seven proteins (Fig 2.5). These are; 
the surface (S) gene which encodes three different proteins, the precore/core (C) gene 
which encodes two different proteins, the X gene, and the polymerase (P) gene which 
are coded on negative strand of DNA [15].  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Structure of HBV DNA and the encoded genes. The nucleocapsid of HBV contains an 
incomplete double-stranded DNA and a DNA polymerase. Four genes (S, C, X, and P) are encoded 
and these partially overlap. The pre-S gene is located upstream of the S gene and consists of the pre-
S1 and pre-S2 genes, and the precore region is located upstream of the C gene [16]. 
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2.2.3 Coding Proteins of HBV 
1- S Gene: The S gene encompasses three regions; the pre-S1, pre-S2, and S. The 
surface proteins are produced by combining these three genes in different 
combinations, like the large protein (LHB) on the envelope is made by encoding the 
pre-S1, pre-S2, and S genes, middle-sized proteins (MHB) on the envelope by 
encoding pre-S2 and S gene and the major component (SHB) of the HBsAg, S 
protein.  Three envelope proteins are not distributed uniformly among the various 
HBV particle types. Subviral 22 nm particles are composed predominantly SHB 
proteins, variable amounts of MHB and few or no LHB proteins, but virus particles 
are enriched for LHB proteins. These proteins carry the receptor recognition domain 
which allows efficient binding to cell surface receptors.  
2- P Gene: The P gene which comprises 80% of the genome encodes the viral 
polymerase capable of acting as a DNA polymerase, RNase H and it binds to 5’ end 
of HBV DNA acting as a primer for reverse transcription of the pregenome, an RNA 
intermediate, to form negative strand DNA. Furthermore, it plays an important role 
in the encapsidation of the viral genomic RNA. The polymerase protein is quite 
immunogenic during both acute and chronic infection. 
3- C Gene: The C gene encodes two related proteins named precore protein and core 
protein. The precore protein is the precursor of the circulating e antigen found in the 
sera of HBV patients, and the core protein is the viral capsid protein. The c antigen 
polypeptide consists of a core domain (residues 1–140) that forms the contiguous 
spherical shell,  and an Arg-rich ‘‘protamine’’ domain (residues 150–183), connected 
by a linker peptide which is responsible for RNA packacing [17]. HBeAg lacks the 
protamine domain, but retains a fragment of signal sequence (Fig 2.6). 
 
Core protein amino acid sequence is: 
1MDİDPYKEFG ATVELLSFLP SDFFPSVRDL LDTASALYRE ALESPEHCSP HHTALRQAİL 
61CWGELMTLAT WVGNNLEDPA SRDLVVNYVN TNVGLKİRQL LWFHİSCLTF GRETVLEYLV 
121 SFGVWİRTPP AYRPPNAPİL STLPETTVVR RRDRGRSPRR RTPSPRRRRS PSPRRRRSQS 
181 RESQC 
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 Figure 2.6: Schematics of precore/core genes and their products. At its 5' end, the precore/core 
gene contains two closely spaced ATGs (black dots) enclosing the precore region, which encodes a 
29-aa precore sequence. Translation of the core mRNA results in the production of the cytoplasmic 
core protein, which assembles into icosahedral capsids enclosing the RNA pregenome, and then the 
nucleocapsids are enveloped and released as complete particles. Precore protein p25 is directed to the 
Endoplasmic reticulum (ER) by a 19-aa-long signal sequence (black boxes) located at its N terminus. 
This signal sequence is removed during translocation into the ER, and then the C-terminal 34-aa-long 
arginine-rich domain (hatched boxes) is eliminated. Mature HBeAg is then secreted. p22cr is a novel 
precore protein identified with HBV DNA-negative particles [18]. 
4- X Gene: The product of X is poorly understood regulatory protein that enhances 
the expression of heterologous and homologous cellular genes in trans. 
2.2.4 Replication of HBV 
The life cycle of HBV begin with the virus attachment to the host cell membrane via 
its envelope proteins [19]. In general, the early step of virus infection in which the 
virus enters the cell can be divided into three stages: attachment, fusion, and entry. 
Enveloped viruses usually enter by an attachment to the host cells, which usually is 
via the interaction of viral surface protein with the specific receptor on the cell 
membrane. Then, the viral membrane fuses with the cell membrane and the viral 
genome is released into the cell [20, 21]. After the viral genome reaches the nucleus, 
the viral polymerase converts the partial double stranded DNA (dsDNA) genome 
into covalently closed circle DNA (cccDNA). The cccDNA is template for further 
propagation of pre-genomic RNA, which directs the synthesis of viral DNA and 
mRNA that encodes all the viral proteins [22, 23, 24]. In the nucleus with the help of 
host’s RNA polymerase, viral RNAs are synthesized. These RNAs act like either 
subgenomic (surface proteins and X protein) or pregenomic RNA (core protein and 
polymerase) according to signal feature in the ORF region of C gene. If mRNA 
decision is subgenomic then, after the translation in cytoplasm the envelope proteins 
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insert themselves as integral membrane proteins into the lipid membrane of the 
endoplasmic reticulum. Precore polypeptide, which is on the C gene, is transported 
into the ER lumen where its amino and carboxyl termini are trimmed and resulted 
protein is secreted precore antigen (HBeAg).  
When mRNA decision is pregenomic, then DNA synthesis takes place in capsids, 
therefore step one is to insert the 3.5 kb mRNA into the capsid. C and P proteins are 
required for the encapsidation, and thus translation must first occur before 
replication.  P first binds to the 5' end of the mRNA strand on a region called epsilon 
stem loop structure (ε). C is then recruited and capsid assembles (Fig 2.7). 
 
 
 
 
 
 
 
 
 
Figure 2.7: Schematic representation of HBV life cycle [25]. 
erred to a DR1 site  at the 3' end of the RNA.  Reverse transcription then 
ensures in the 5'--> 3' direction until the 5' end of the RNA is reached. As replication 
ccurs, the RNAase activity of P releases the mRNA strand. Once this (-) DNA 
strand has been replicated, P then jumps to a region on the newly synthesized DNA 
trand called DR2, which is located close to the DR1 site 5' end of the newly 
ynthesized strand. P brings along a small 18 nucleotide, capped region from the 5' 
end of the RNA which RNAase does not destroy, and uses it as a primer for the 
 P is transf
o
s
s
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synthesis of the second  (+) DNA strand. Because DR2 is farther downstream than 
DR1, the second (+) DNA strand to be synthesized is slightly shorter than the first.  
The new, mature, viral nucleocapsids can then follow two different intracellular 
athways, one of which leads to the formation and secretion of new virions, whereas 
the other leads t eus. 
p
o amplification of the viral genome inside the cell nucl
In the virion assembly pathway the nucleocapsids reach the ER where they associate 
with envelope proteins and bud into the lumen of the ER, from which they are 
secreted via the golgi apparatus out of the cell.  
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 3. THE IMMUNE SYSTEM 
he immune system is a network of cells, tissues, and organs that work together to 
s by “foreign” invaders. The immune system’s job is 
to keep this invaders out or to seek out and destroy them. The most important feature 
f this system is to distinguish the structure between foreign and its own molecule.  
hen an organism is threatened by microorganisms and viruses, the immune 
response acts to provide protection. Anything that causes an immune response is 
called an antigen. An antigen may be harmless, such as grass pollen, or harmful, such 
as the flu virus. Disease-causing antigens are called pathogens. The immune system 
 designed to protect the body from these pathogens. 
Immune system response is specific to antigens, each response is given for each 
antigene and each response will be taken to memory. There are three types of 
immune response. These are innate immunity, adaptive immunity and passive 
s 
T
defend the body against attack
o
W
is
immunity [26]. 
3.1 Innate (natural) Immunity 
Microorganisms that successfully enter an organism will encounter the cells and 
mechanisms of the innate immune system. Innate immune defenses are non-specific, 
meaning these systems recognize and respond to pathogens in a generic way. Thi
system does not confer long-lasting immunity against a pathogen. The innate 
immune system is the dominant system of host defense in most organisms [27]. 
 
15 
 
Innate immunity also includes the external barriers of the body, like the skin and 
mucous membranes which are our first line of defense in preventing diseases from 
entering the body. If this outer defensive wall is broken (like if you get a cut), the 
uickly and special immune cells on the skin attack 
nfant 
nd protect against bacterial infections until the newborn can synthesize its own 
antibodies [28]. This is passive immunity because the fetus does not actually make 
any memory cells or antibodies it only borrows them. In medicine, protective passive 
immunity can also be transferred artificially from one individual to another via 
antibody-rich serum [29]. 
3.3 Adaptive Immunity 
The adaptive immune system is evolved in early vertebrates and allows for a stronger 
immune response as well as immunological memory, where each pathogen is 
"remembered" by a signature antigen [30]. The adaptive immune response is antigen-
specific and requires the recognition of specific antigens during a process called 
antigen presentation. Antigen specificity allows for the generation of responses that 
are tailored to specific pathogens or pathogen-infected cells. The ability to mount 
these tailored responses is maintained in the body by "memory cells". Pathogen 
should infect the body more than once, these specific memory cells are used to 
quickly eliminate pathogen. On the other hand, vaccine applications can be a good 
example for the adaptive immunity. 
There are two broad immune response classes for adaptive immunity. These are; 
Antibody Responses and Cell-Mediated Immune Responses. These responses are 
carried out by different classes of lymphocytes, called B cells and T cells, 
respectively [31]. 
 
skin attempts to heal the break q
invading germs. 
3.2 Passive Immunity 
Passive immunity is "borrowed" from another source and it lasts for a short time. For 
example, breast milk contains antibodies that are transferred to the gut of the i
a
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In antibody responses, B cells are activated to secrete antibodies, which are called 
immunoglobulins. The immunoglobulins circulate in the bloodstream and permeate 
the other body fluids, where they bind specifically to the foreign antigen that 
stimulates their production. Binding of antibody inactivates viruses and microbial 
toxins such as tetanus toxin by blocking their ability to bind to receptors on host 
cells.  
ptive immune response is cell-mediated immune responses. 
 
 
 
The second class of ada
In this response system, activated T cells react directly against a foreign antigen that 
is presented to them on the surface of a host cell. The T cell, for example, might kill 
a virus-infected host cell that has viral antigens on its surface, thereby eliminating the 
infected cell before the virus has had a chance to replicate. In other cases, the T cell 
produces signal molecules that activate macrophages to destroy the invading 
microbes that they have phagocytosed [32,33].  
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 4. THE ANTIBODY 
Antibodies are serum immunoglobulins that have binding specificity for particular 
antigens. All antibody molecules have the same antigen binding site. The first 
antibodies made by a newly formed B cell are not secreted. Instead, they are inserted 
onto the plasma membrane, where they serve as receptors for antigen. The other type 
of antibodies are soluble antibodies that are free in the blood, lymph and tissue 
fluids. When B cell is activated by an antigen with the aid of a helper T cell, it 
proliferates and differentiates into an antibody-secreting effector cell. Such cells 
ake and secrete large amounts of soluble antibody, which has the same unique 
ntigen-binding site as the cell-surface antibody that served earlier as the antigen 
ceptor. Effector B cells can begin secreting antibody while they are still small 
mphocytes, but at the end stage of their pathway, they mature into a large plasma 
ell [33].  
he simplest antibodies are Y-shaped molecules with two identical antigen-binding 
ites (Fig 4.1). Because of their two antigen-binding sites, they are described as 
ivalent. The efficiency of antigen binding is greatly increased by a flexible hinge 
gion in most antibodies, which allows the distance between the two antigen-
inding sites to vary. The protective effect of antibodies is not due simply to their 
bility to bind antigen. They engage in a variety of activities that are mediated by the 
il of the Y-shaped molecule. Antibodies with the same antigen-binding sites can 
ave any one of several different tail regions. Each type of tail region gives the 
ntibody different functional properties, such as the ability to activate the 
omplement system, to bind to phagocytic cells, or to cross the placenta from mother 
 fetus. 
m
a
re
ly
c
4.1 Molecular Structure 
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The basic structural unit of an antibody molecule consists of four polypeptide chains, 
two identical light (L) chains each containing about 220 amino acids and two 
identical heavy (H) chains each usually containing about 440 amino acids [34]. The 
four chains are held together by a combination of noncovalent and covalent 
posed of two identical halves, each with the 
same antigen-binding site. Both light and heavy chains usually cooperate to form the 
tant (CL) domain. Variable and constant domains pair with the variable 
eavy (VH) and first constant (CH1) domain of the heavy chain to form the antigen-
inding region. The remaining constant domains of the heavy chains form the Fc 
(disulfide) bonds. The molecule is com
antigen-binding surface. A light chain has one variable (VL) and one constant (CL) 
domain, while a heavy chain has one variable (VH) and three or four constant (CH) 
domains. The amino acid sequence variation in the variable domains of both light 
and heavy chains is mainly confined to several small hypervariable regions, which 
protrude as loops at one end of the domains to form the antigen-binding site. 
 
 
Figure 4.1: Typical antibody [35]. 
4.2 Isotypes and Function 
Both light and heavy chains are made up of repeating segments. These repeating 
segments fold independently to form compact functional units called 
immunoglobulin (Ig) domains. A light chain consists of one variable light(VL) and 
one cons
h
b
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region, which determines the other biological properties of the antibody. Most heavy 
chains have three constant domains (CH1, CH2, and CH3), but IgM and IgE antibodies 
have four.  
In mammals, there are five classes of antibodies, these are IgG, IgA, IgE, IgG, and 
IgM, each has its own class of heavy chain. (δ, ε, γ, and μ, respectively) [34]. 
1-) IgG: The IgG molecule may be thought of as a ‘typical’ antibody. It is the major 
immunoglobulin in normal human serum. Approximately, 75% of the total 
immunoglobulin pool is IgG.  They are large molecules, having a molecular weight 
of approximately 150 kDa. It is composed of two different kinds of polypeptide 
chain. One  is termed the heavy chain which is 50 kDa, and the other one is termed 
the light chain which is 25 kDa. Each IgG molecule consists of two heavy chains and 
two light chains. This is the only isotype that can pass through the human placenta, 
thereby providing protection to the fetus in its first weeks of life before its own 
immune system has developed. It can bind to many kinds of pathogens, for example 
viruses, bacteria, and fungi, and protects the body against them by complement 
activation (classic pathway), opsonization for phagocytosis and neutralization of 
their toxins. There are four subclasses: IgG1 (66%), IgG2 (23%), IgG3 (7%) and 
IgG4 (4%). 
2-) IgA: IgA is the main immunoglobulin in mucous secretions, including tears, 
saliva as well as respiratory, intestinal secretions. It has 472 amino acid residues of 
the alfa(α) chain arrange in four domains: VH, Cα1, Cα2 and Cα3. Its heavy chains 
are of the type α. It exists in two forms, IgA1 (90%) and IgA2 (10%) that differ in 
the structure. IgA1 is composed like other proteins, however in IgA2 the heavy and 
light chains are not linked w ent bonds. 
3-) IgE: IgE has ε heavy chain which has a  molecular weight of the 72 500 Da. Its 
 residues (approximately 550) are distributed over five 
ith disulfide but with noncoval
larger number of amino acid
domains VH, Cε1, Cε2, Cε3 and Cε4. IgE is found on the surface membrane of 
basophils and mast cells in all individuals. The soluble IgE antibodies bind to Fc 
receptor proteins on the mast cell or basophil surface that specifically recognize the 
Fc region of these antibodies. Antigen binding triggers the mast cell or basophil to 
secrete a variety of cytokines and biologically active amines, especially histamine. 
These molecules cause blood vessels to dilate and become leaky, which in turn helps 
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white blood cells, antibodies to enter sites of infection. The same molecules are also 
largely responsible for the symptoms of such allergic reactions as asthma, and hives. 
4-) IgM: IgM is the class of immunoglobulin characterized by μ heavy chains. It is 
 units, 
tes (coexpressed with IgM) and is also found in serum in very small 
the first immunoglobulin to appear on the surface of B cells and the first to be 
secreted. In its secreted form, IgM is a pentamer composed of four chain
giving it a total of 10 antigen-binding sites. Each pentamer contains one copy of 
another polypeptide chain, called a J (joining) chain. The J chain is produced by IgM 
secreting cells and is covalently inserted between two adjacent tail regions.  The 
immediate precursor of a B cell, called a pre-B cell, initially makes μ chains which 
associate with so called surrogate light chains (substituting for genuine light chains) 
and insert into the plasma membrane. The complexes of μ chains and surrogate light 
chains are required for the cell to progress to the next stage of development. The 
light chains combine with the μ chains, replacing the surrogate light chains, to form 
four-chain IgM molecules. These molecules then are inserted into the plasma 
membrane, where they function as receptors for antigen. At this point, the cell is 
called an immature B cell. 
5-) IgD: IgD makes up about 1% of proteins in the plasma membranes of immature 
B-lymphocy
amounts. This protein is more susceptible to proteolysis than IgG1, IgG2, IgA or 
IgM, and also has a tendency to undergo spontaneous proteolysis. There appears to 
be a single disulphide bond between the δ chains and a large amount of carbohydrate 
distributed in multiple oligosaccharide units. 
4.3 Monoclonal Antibodies  
Monoclonal antibodies are produced by a single clone of B lymphocytes. 
Monoclonal antibodies are usually produced by making hybrid antibody-forming 
cells from a fusion of nonsecreting myeloma cells with immune spleen cells. 
Hybridoma Technology is used for production of monoclonal antibodies. In this 
technique, the idea is combining two useful cells together. Myeloma cells that have 
immortality and rapid reproduction features are fused with spleen cells which can 
produce our desired antibody from immunized animal. Thus, immortal hybrid cells 
are produced against to one determining group (epitope) of a complex antigen [36]. 
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Immune diagnostic systems are improved for use in agriculture, medicine and 
enviroment by the help of antibody-antigen reactions. These systems are based on the 
ted in a hybridoma that produced a single antibody by the 
immortal cells that lose their reproduction control 
mechanism. 
antibody-antigen reactions that can be detected by radioactive or flourescent 
molecules and enzimatic reactions such as ELISA and RIA ( Radio Immune Assay). 
The most important factor for this system is specificity of the antibody to the 
detecting antigen. 
4.4 Production of Monoclonal Antibodies: Hybridoma Technology 
In history, scientist felt a desire for generating antibodies on a large scale, specific 
and pure. For this purpose, the general idea is selecting a B cell that produces the 
antibody of interest and expanding that population among the library of B cells [37]. 
The process of producing monoclonal antibodies (MAb) described above generally 
was invented by Georges Köhler, César Milstein, and Niels Kaj Jerne in 1975. They 
shared the Nobel Prize in Medicine in 1984 for this discovery. Their technique was 
to immunize mice with a pathogen and then fuse the animal’s splenic B cells with 
myeloma cells, which resul
immortalized selected B-cell line. These hybridomas can produce unlimited 
quantities of monoclonal antibodies directed at a specific epitope of the desired 
pathogen with high specifity. 
In Hybridoma Technology people can take advantage of three pieces of information 
1-) B lenfosites are blood cells which can produce and secrete antibody for specific 
epitope, and can have a limited life time up to  4-5 days. 
2-) Myeloma cells are the 
3-) By combining two different cells from the same organism in a specific 
conditions, hybridomas carrying features of the two cell can be produced. 
In Hybridoma Technology, immunized animal’s lymphocyte cells are fused with 
myeloma cells, and the process is named as “cell fusion”. Thus, natural B cells are 
returned into antibody factory in a culture medium.  
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Steps of the hybridoma technology are shown below, 
1-) In order to produce antibody against the desired antigen, mice are immunized 
with desired antigen. Then, the most actively immunized mouse is selected by 
ELISA method.  
2-) The most actively immunized mouse’s spleen is taken to isolate antibody 
producing B lymphocyte and myeloma cells are prepared. 
two types of 
cells. 
 
cells to die. Meanwhile, remained hybridomas are continuing to divide in culture 
f single cell. 
 
r in vivo (by formation of 
antibodies could be purified with appropriate methods. 
3-) To produce hybridoma, polyethylenglycol (PEG) is used to fuse 
4-) Cells that are subjected to fusion in a culture medium, will then be incubated in 
Hypoxanthine Aminopterin Thymidine medium (HAT medium) waiting unfused
plates. 
5-) Hybridoma clones that produced antibodies for desired antigen are detected by 
ELISA method. 
6-) In this stage, there can be more than one hybridoma colony in a well which can 
produce polyclonal antibody. By using “limited dilution” method, selected cells in 
wells are dispersed to new culture plates in order to get hybrids (immortal B 
lymphocyte) from the origin o
7-) Hybridoma colonies that synthesize specific antibody for desired antigen can be
selected by ELISA method. 
8-) Selected hybridomas produce large quantities eithe
ascites in mouse) or in vitro (in cell culture). 
9-) Produced 
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 Figure 4.2: General steps for production of monoclonal antibodies [38]. 
4.5 Application Fields of Monoclonal Antibodies  
Monoclonal antibodies have a variety of medical and commercial uses. Following 
ounts of drugs, 
toxins or hormones, For example, monoclonal antibodies to human chorionic 
gonadotropin (HCG) are used in pregnancy test kits. Another diagnostic uses of 
antibodies is the diagnosis of AIDS by the ELISA test. 
 
 
 
list should indicate how ubiquitous monoclonal antibody technology has become in 
biotechnology. 
1-) Antibodies are used in several diagnostic tests to detect small am
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2-) Antibodies are used in the radioimmunodetection and radioimmunotherapy of 
cancer, and some new methods can even target only the cell membranes of cancerous 
cells [39]. A new cancer drug based on monoclonal antibody technology is Ritoxin 
which binds to the CD20 molecule found on most B-cells and is used to treat B-cell 
lymphomas, approved by the US Food and Drug Administration (FDA) in November 
1997 [40].  
3-) Monoclonal antibodies can be used to treat viral diseases, traditionally considered 
"untreatable". In fact, there is some evidence to suggest that antibodies may lead to a 
cure for AIDS. 
4-) Monoclonal antibodies can be used to classify strains of a single pathogen, e.g. 
Neisseria gonorrhoeae can be typed using monoclonal antibodies [41].  
5-) Researchers use monoclonal antibodies to identify and to trace specific cells or 
molecules in an organism. For example developmental biologists use monoclonal 
antibodies to find out which proteins are responsible for cell differentiation in the 
respiratory system [42]. 
6-) OKT3, an antibody to the T3 antigen of T cells, is used to alleviate the problem 
of organ rejection in patients who have had organ transplants.  
When we summarize these items, monoclonal antibodies are currently used in fields 
• measuring protein and drug levels in serum  
ng infectious agents  
• identifying specific cells involved in the immune response  
• identifying and quantifying hormones  
    ●    imaging the target with a fluorescent molecule attach to antibody (Fig 4.3) 
      ●    killing the target with a strongly-radioactive atom, such as Iodine-131  
including:  
• typing tissue and blood  
• identifyi
• identifying clusters of differentiation for the classification and follow-up 
therapy of leukemias and lymphomas  
• identifying tumor antigens and auto-antibodies  
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 Figure 4.3: Rat neurons and glia stained with fibrillarin antibody (green), and chicken NF-H 
antibody (red) [43]. 
4.6 Hepatitis Virus Test and Core Antibody Importance 
Hepatitis B virus tests look for substances in the blood that show if a hepatitis 
infection is acute, chronic, or is occurred in the past. The tests look for antigens, 
antibodies, or genetic material of the virus that causes hepatitis. It is important to 
identify the type of hepatitis virus causing infection to prevent its spread and begin 
the proper treatment. 
Hepatitis B surface Antigen is one of the most frequently performed tests for HBV. 
This HBV antigen is the earliest indicator of an active hepatitis B infection. This 
antigen BV infection are present. The  may be present before symptoms of an H
incubation of the HBV is between 6 to 25 weeks. After infection and 1 to 6 weeks 
before symptoms occur HBsAg appears. A positive test for the presence of HBsAg is 
the n te current infection with hepatitis B. If HBsAg sta dard currently taken to indica
is p eres nt for more than 6 months this is generally taken to indicate chronic infection. 
Hepatit bout 4 weeks after HBsAg disappears is B surface antibody usually appears a
and i ve stage and you cannot pass  th s means that the infection is at the end of its acti
the virus to others. This antibody also protects you from getting HBV again in the 
futu .  antibody will be re The test is done to determine the need for vaccination. The
pre t s, showing that you have protection sen  after receiving the HBV vaccine serie
from the virus. 
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Currently, there is no test to find Hepatitis B core Antigen (HBcAg). Because this 
antigen disappears early in the course of infection and it is difficult to be detected in 
patients’ serum, it can be tested only by biopsy from the liver. Sometimes this 
application is not necessary, since general information can be obtained from IgM 
specific HBcAg  patients blood.  
Hepatitis core Antibody (HBcAb) is an antibody to the hepatitis B core antigen. It is 
the first detectable antibody to appear around 8 weeks after infection with HBV [1]. 
HBcAb is considered a sensitive and specific serum marker of HBV infection. In 
some patients, HBcAb is the only marker of HBV infection. This finding could be 
due to false-positive results of reactivity testing, loss of HBsAb with time or failure 
of patients to develop HBsAb after HBV infection.  
HBcAb appears 5-14 days after Hepatitis e Antigen (HBeAg) and can be found 
shortly before HBsAg is no longer detectable. The period between the disappearance 
of HBsAg and the appearance of HBsAb is often called “core window” (Fig 4.4). 
HBcAb persists for months to years after resolution of acute hepatitis B, and also 
persists in cases of chronic infection. However, the demonstration of IgM-specific 
HBcAb is evidence that the patient is in an acute infection. Conversely, the absence 
of IgM core antibody in a patient with long-term B surface antigenemia suggests 
chronic hepatitis B viral infection.  
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l protein is unknown; however, it is thought that 
HBeAg may be influential in suppressing the immune systems response to HBV 
infection. HBeAg is generally detectable at the same time as HBsAg and disappears 
before HBsAg disappears. The presence of HBeAg in chronic infection is generally 
taken to indicate that HBV is actively reproducing and there is a higher probability of 
liver damage. In acute infection, HBeAg is generally only transiently present. 
4.7 Polyclonal Antibodies  
Polyclonal antibodies are derived from different B-cell lines. They are a mixture of 
immunoglobulin molecules secreted against a specific antigen, each recognising a 
different epitope. Monoclonal and polyclonal antibodies are produced using different 
techniques (Table 4.1). Both antibody types have distinct advantages and choosing 
one over the other will depend on the experimental use. Polyclonals are raised by 
repeated immunizations of a host animal such as rabbit, chicken, rat and by 
 
 
Figure 4.4: Serolojical and clinical patterns observed during acute Hepatitis B viral infection [44]. 
Hepatitis e Antigen (HBeAg) is a peptide and normally detectable in the bloodstream 
when the hepatitis B virus is actively reproducing, this in turn leads to being much 
more infectious to the person and at a greater risk of progression to liver disease. The 
exact function of this non-structura
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d s can be 
purified from the serum. In contrast, monoclonals are produced by immunizing a 
mouse and by generating hybridomas from the fusion of the spleen cells with 
myeloma cells. Cloned hybridomas will produce identical copies of the same 
antibody. 
Table 4.1: Comparing of monoclonal and polyclonal antibodies 
Monoclonal Polyclonal 
 
• Homogeneous: one antibody 
type, identical antibodies 
specific to only single 
epitope 
  
constant and renewable 
multiple MAbs of desired 
 
• Heterogeneous: serum contains a 
complex mixture of antibodies 
of different affinity  
 
• Large quantities of antibodies 
 
 
ieharvesting the serum that contains the antibodies. Polyclonal antibo
• Hybridoma is immortal: can be produced rapidly  
source of antibody 
                         
• is useful in evuluating 
changes in molecular 
conformation, protein-protein 
interactions 
 
• Too expensive, time 
consuming to identify 
• Variety of hosts possible 
 
• Production is much more rapidly 
and cheaply 
 
• More stable over a broad pH 
 
• Limited by size of animal and its 
lifespan 
specifity 
4.8 The Antigen 
An antigen is a substance that can specifically bind to immune system receptors like 
T cell receptor or major histocompatibility complex (MHC) molecule to initiate an 
immune system response. Many different types of molecules can serve as antigens 
including proteins, nucleic acids (DNA, RNA), lipids, carbohydrates. On the other 
hand, immunogens are the antigens because they can induced an immune response 
by binding to immune system receptors. But, all antigens are not immunogens. 
Immunogen antigens can have a phospholipids, carbohydrate and protein structure. 
Antigens which are not immunogens can easily escape from the immune system. 
They can give an immune response if they bind to a carrier protein. This kind of 
Antibodies do not produce response against whole  structure, they 
produce against to small polypeptite sequences which are called immunogen 
antigen t). i he 
antigen and it can be diverse and many. An antigen can be recognized by the 
antibodies  that epitope ne system cell 
receptors [
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
response is called hapten. 
 immunogen
’s epitope (antigenic determinan
which are specific to
45,46]. 
Th s epitope is a specific part of t
or responsible immu
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 5. EXPERIMENTAL 
5.1 Features of Chosen Animals for Immunization 
 
he age of the animals is another important consideration because various factors 
an influence the outcome of the immunization. It is important to use young adults 
 the immune response is robust and not affected by 
revious immune challenges. The robustness of the immune response decreases with 
ge after the period of young adulthood. On the other hand, although mice are inbred, 
ice are genetically similar with each other; hence, their immune response 
ferent. In addition to this, mice can die for different reasons in this 
munization period. In order to prevent this kind of side effect, 6-8 weeks old mice 
 addition to these, the sex of the animals must be decided. Traditionally, female 
nimals are used for MAb production. Female animals can be group housed more 
uccessfully than males because females are more docile and less aggressive in social 
teraction [48]. There are however, no overriding scientific reasons for not using 
ale animals for MAb production. 
inally, it is important to consider the health status of animals used for the 
roduction of antibodies. Infectious agents may suppress, modulate, or stimulate the 
mune system. The use of disease-free animals minimizes the likelihood of cross-
activity to other antigens the animal’s immune system may have encountered [49]. 
Mice and rats are selected for immunization generally in hybridoma technology. 
They are easy to obtain, easy to fatten and breed, inexpensive to get and they both 
give good response to immunization. Usually, Balb/C originated mice strains are 
used because of their positive response against to desired antigen, like greater ascites 
volumes and antibody production [47].
T
c
such as 6-8 weeks old, for whom
p
a
not all m
will be dif
im
can be selected. 
In
a
s
in
m
F
p
im
re
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5.2 Features of Cells for Fusion 
The choice of rat or mouse strains for use in monoclonal antibody production is 
normally constrained by the sources from which the myeloma cell lines were 
derived. Thus, Balb/C mouse strain is preferred. Because, myeloma cell lines have 
ginally induced in such animals and they are therefore 
compatible for the propagation of hybridoma cells in vivo. 
For monoclonal antibody production, only the myeloma cell lines are used which 
he line, known as Sp2/0-Ag14, showed a 
different hybrid cells in the enviroment 
r hybrid cells. 
 
ihydrofolate reductase. The trick is that aminopterin blocks DNA "de novo" 
ynthesis, which is absolutely required for cell division to proceed, but the 
been derived were ori
could not have a capacity to secrete immunoglobulin molecules of their own. Since it 
reduces the proportion of hybrids which potentially will secrete lymphocyte derived 
antibodies.  
For the first time, a non-immunoglobulin producing mouse myeloma cell line was 
isolated by Schulman et al in 1978. T
variable efficiency of fusion although it was recognized as a potentially useful 
partner for generating hybridomas making truly monoclonal antibodies. Kearney et al  
identified another mouse myeloma cell line (X63-Ag8-653) in 1979 that had lost the 
capacity for immunoglobulin expression but which still permitted the formation of 
antibody secreting hybrid cell lines [47]. 
5.3 Post Fusion Selection Criteria for Cells 
Cell fusion for the immortalization of spleen cells requires a means of selection for 
mixed hybrids. After the fusion, there can be 
such as B lymphocyte-B lymphocyte hybrid cells, myeloma-myeloma hybrid cells, 
non-fusion of B lymphocyte cell and myeloma-B lymphocyte hybrid cells. To select 
the endless monoclonal antibody production ability of myeloma-B lymphocyte 
hybrids from the others, all the cells are put into the HAT medium after fusion in 
order to separate them from the othe
The favoured selection procedure depends on the capacity of cells to use the “salvage 
pathway” for guanosine production when the main biosynthetic “de nova pathway” is 
blocked usually by putting the antibiotic aminopterin into the medium (Fig 5.1). 
Aminopterin is a drug that acts as a folate metabolism inhibitor by inhibiting
d
s
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hypoxanthine and timidine, which are intermediates in DNA synthesis, provide cells 
with the raw material to evade the "salvage pathway". This salvage pathway relies on 
y for the formation of the 
purine precursors of DNA are blocked. However, a cell which is HGPRT(-) will grow 
GPRT(+) hybrids in the HAT medium.  
the presence of the enzyme hypoxanthine guanine phosphoribosyl transferase 
(HGPRT).  
Cells lacking this enzyme will die when grown in media containing hypoxanthine, 
aminopterin and thymidine because both pathways necessar
in the selection medium if it is fused with a cell which is HGPRT(+). Myelomas 
which are HGPRT(-) needed for successful selection of myeloma HGPRT(-) and 
spleen cell H
 
Figure 5.1: De novo and salvage pathways for nucleotide synthesis.  In a normal medium, cultured 
animal cells synthesize purine nucleotides (AMP, GMP, IMP) and thymidylate (TMP) by de novo 
pathways (blue). These require the transfer of a methyl or formyl group from an activated form of 
tetrahydrofolate (e.g., N5,N10-methylenetetrahydrofolate), as shown in the upper portion of the 
diagram. Antifolates, such as aminopterin, block the reactivation of tetrahydrofolate, preventing 
purine and thymidylate synthesis. Normal cells can also use salvage pathways (red) to incorporate 
purine bases. Cultured cells lacking one of the enzymes of the salvage pathways — HGPRT, APRT, 
or TK — will not survive in media containing antifolates [50]. 
After the fusion in HAT culture medium, myeloma/myeloma hybrid cells and 
unfusioned myeloma cells which are HGPRT (-) disappear from the culture in 8-9 
days (Table 5.1). Unfusioned B lymphocyte cells which are TK and HGPRT (+), B 
lymphocyte/ B lymphocyte and myeloma / B lymphocyte hybrid cells continue to 
live for a finite time.  
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Unfusioned B lymphocyte cells and B lymphocyte/ B lymphocyte hybrid cells die in 
4-5 days because of not having immortality feature. Thus, required myeloma/B 
lymphocyte hybrid cells are selected from the other hybrids [51]. 
Table 5.1: Post fusion cell features [47]. 
 
5.4 Immune Response Detection: Enzyme-Linked ImmunoSorbent Assay 
(ELISA) 
Enzyme-Linked ImmunoSorbent Assay (ELISA) is a biochemical technique used 
mainly in immunology to detect the presence of an antibody or an antigen in a 
sample. The ELISA is used as a diagnostic tool in medicine and plant pathology, as 
well as a quality control check in various industries [52]. Performing an ELISA 
involves at least one antibody with specificity for a particular antigen.  
 or semi-purified antigen are 
 test solution antibodies) is then added to the plate. After 
incubation, unbound conjugate is washed away and substrate solution is added.  
We can separate ELISA systems mainly in 4 groups:  
1- ) Indirect ELISA: 
This assay is useful for screening antisera or hybridoma supernatants for specific 
antibodies when milligram quantities of purified
available. Antibodies are detected by coating the wells of microtiter plates with 
antigen, incubating the coated plates with test solutions containing specific 
antibodies, and washing away unbound antibodies [53]. A solution containing a 
developing reagent, (e.g., alkaline phosphatase conjugated to protein A, protein G, or 
antibodies against the
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Following a second incubation, the amount of substrate hydrolyzed is assessed with a 
spectrophotometer or spectrofluorometer (Fig 5.2). The measured amount is 
proportional to the amount of specific antibody in the test solution [54, 55]. 
The direct ELISA is a method for detecting and measuring antigen concentration in a 
sample. It is originated in the 1940s when Coons and colleagues labeled antibodies 
with a flourescent tag to mark antigens [56]. Using a capture monoclonal antibody, 
the presence of a particular antigen in a sample is detected. In this type of ELISA, 
produced monoclonal antibodies are labeled with an enzyme and does not need 
second antibody for detection of the antigen. Direct detection is not widely used in 
ELISAs, but is quite common for immunohistochemical staining of tissue and cells. 
2- ) Direct ELISA:  
3- ) Competitive ELISA:  
Main purpose on this ELISA is detecting the amount of desired antigen/antibody in 
the sample. Competition assays are defined as assays where the detecting 
antibodies/antigens are added with the sample simultaneously. Competition assays 
imply that two reactants are trying to bind to a third. 
4- ) Sandwich ELISA 
Sandwich ELISAs may be the most useful of the immunosorbent assays for detecting 
antigen because they are frequently between 2 and 5 times more sensitive than those 
in which antigen is directly bound to the solid phase. To detect antigen, the wells of 
microtiter plates are coated with specific (capture) antibody followed by incubation 
with test solutions containing antigen. Unbound antigen is washed out and a different 
antigen-specific antibody conjugated to enzyme (i.e. developing reagent) is added, 
followed by incubation. Unbound conjugate is washed out and substrate is added. 
After incubation, the degree of substrate hydrolysis is measured. The amount of 
substrate hydrolyzed is proportional to the amount of antigen in the test solution [55]. 
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Figure 5.2: ELISA formats [57]. 
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6. MATERIALS and METODS 
6.1 Equipments 
There are some pieces o wing cells in hybridoma 
quirements related to pruduction of hybridomas.   
-) Clean Area: Tissue culture would be carried about in rooms having their own 
ltered air supply. The location of culture laboratory must be given careful 
onsideration. For example, not to be situated near microbiological work area, and 
ot to be opened directly to the corridors. In our studies, we used The Class II 
iological Safety  Laboratory. 
-) Laminar Air Flow Cabinets: All necessary manipulations of culture medium and 
ells should be carried out in a sterile enviroment, in order to prevent contamination 
y airborne organisms. Such an enviroment is provided by laminar air flow or hoods 
o that filtered air is directed over the work area. The filters that are used are high 
fficiency particle filters (HEPAs) capable of removing from air paticulate matter 
at is greater than 0.3 μm in diameter. During hybridoma studies we used vertical 
minar flow by Heraeus Cytoperm II. 
-) Incubators: Most cells from endothermic animals need to be kept at a temperature 
f 37°C for optimal growth. However, in the case of monoclonal antibody 
roduction, hybridoma cells prefer conditions in which bicarbonate acts as a 
uffering ion, helping to maintain the pH of the culture medium. Thus, the incubators 
quired should be capable of maintaining an internal atmosphere of 5% CO2. In the 
tudy, Cytoperm marked incubators were used. 
-) Microscopes: For hybridoma work, 10X and 20X objective with 10X-15 eye-
ieces give sufficient magnification of 200-300 for both scanning and detailed 
bservation of cultures. In our laboratory, we used inverted phase-contrast (Olympus 
KX41A) and light microscope (Olympus). 
f equipment required for gro
technology. Some of them are specific laboratory equipments, technics and 
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5-) Filtration Devices: Culture medium and the various additives necessary to sustain 
living cells cannot be sterilised by heat. However, filtration through 0.2 μm pore size 
filter will remove most  microorganisms likely to contaminate tissue culture. Filters 
can be obtained as disposable sterile units or reusable units, in which only the filter 
 
paper is replaced (Fig 6.1).  
 
Figure 6.1:  Filtration systems (in the left picture)  culture mediums are filtrated by this 
system. There are  disposable filtration devices (in the right picture). 
6-) Pipetting Devices: 1000μl, 100 μl, 10 μl Transfer Pipettes from Trefflab were 
used in the study. 
7-) Freezers: Fridge and freezers are standard storage equipment in ordinary 
laboratories, including tissue culture. Culture medium is stored at 4 C and -20 C 
8-) Centrifuge: The washing, concentrating, and pelleting of cells requires 
  
  
° °
freezer is necessary for the storage of certain reagents to be added to culture medium, 
particularly fetal calf serum, which is normally ordered in large batches. -70°C 
freezer is usually necessary as part of the process of freezing cells and for their short-
term storage. The long-term preservation of cells requires storage at even lower 
temperatures, in liquid nitrogen tanks. During this study, Union Carbide Nitrogen 
Tanks are used . 
centrifugation at approximately 1500 rpm. In this study we used Sorvall RC5C Plus 
and Eppendorf desktop centrifuge  marked systems. 
9-)  Water Bath (37 °C) from Scientific Industries. 
10-) ELISA Reader from Biotech 
11-) Spectrophotometer from Bio-Rad 
12-) Magnetic stirrer from Cole Parmer 
 13-) Vortex from Scientific Industries 
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14-) Polyacrilamide gel (PAGE) supplies from Bio-Rad 
15-) Steril disposable polistren pots, plates from Nunc and TPP Company 
 y      ELISA Plates (96 wells) 
 y      Centrifuge Tubes (10 ml, 50 ml) 
      Fusion Plates (96 wells) 
 y      Coaster (4-6-24 wells) 
16-) Freezing tubes from TPP Company 
17-) Scissors, Pliers, Strainer, Mortar from Sigma 
 Schott 
21-) Cell Growth Containers (petri dishes): There are many different forms of 
 
Figure 6.2: Cell Growth Containers 
 
  
 y
18-) Autoclable Glass Bottle (50-1000cc) from
19-) Thomas microscope slide for cell counting from Sigma 
20-) Injector (1-25 cc) from Ayset  
disposable plastics, suitable for cell culture, ranging from multiwell dishes holding as 
little as 200 μl well to roller bottles. Some are treated to encourage attachment of 
particular cell types, but all are supplied sterile and are of such quality as not to 
impair observation under the microscope. Disposable cell growth containers of 25 
cm2, 75 cm2, 150 cm2 were used from Nunc (Fig 6.2).  
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 22-) Anti-mouse polyvalent immunglobulins (IgG-IgM-IgA) Alkaline Phosphatase  
        Conjugate from Sigma A:0162 
23-) Anti-rabbit IgG from Sigma A:3812 
   24-) P-NitrophwnlyPhosphate from Sigma N-3254 
25-) Dulbeco’s Modified Eagle’s Medium from Sigma D-6780 
26-) Freund’s Adjuvant Complete from Sigma F-5881 
   27-) Freund’s Adjuvant Incomplete from Sigma F-5506  
   28-) Fetal Bovine Serum(FBS) from Biochrom S0115 
29-) Dimethyl sulphoxide (DMSO) from Fluka 
   30-) Gentamisin from Gibco 
   31-) Fetal Calf Serum from Biochrom(FCS) 
  
  
   35-) 8-Azoguanin from Sigm
   36-) Ammonium persulphate (APS) from Sigma 
   37-) Milk Powder from P
   38-) Tween 20 from Me
   39-) Ammonium sulphate from
   40-) N, N, N', N'-tetrame  Sigma 
   41-) Membranes, Immobilon-P 
   Membrane from Sigma 
   42-) HiTrap Protein A HP, 1 ml and 5 ml from Amersham Biosciences 
   43-) Subisotyping Kit fro
 
 32-) Bovine Serum Albumin(BSA) from Sigma 
33-) Hypoxanthine aminopterin thymidine (HAT) from Gibco 
 34-) Para nitrophenyl phosphate (PNPP) from Merck 
a 
ınar Süt AŞ. 
rck 
 Merck 
thyl ethylenediamine (TEMED) from
SQ  Polyvinylidene Difluoride (PVDF) Transfer    
m Bohrienger Mannheim 
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6.2 Media, Buffer and Chemical Preparation 
6.2.1 Buffer Preparations 
PBS Buffer: Buffer is prepared in pH 7.2. This pH is balanced with adding 10 
l is added. 
   
   mM K2HPO4 to 10 Mm KH2PO4. Then, 0.15 M NaC
PBS-Tween 20 Buffer: %0,05 tween 20 is added to PBS buffer.  
Substrate Buffer: 1 Mm ZnCl2, 1Mm MgCl2, 0.1M Glisin are added, and pH is 
l substrate 
buffer and it was kept at dark. 
PEG Solution:
balanced  with  KOH to 10.4. While using, 1 mg PNPP was put into 1 m
 2 gr PEG, 1 ml Distil water, 1 ml PBS added, then sterilized with 
°C. autoclave. After the sterilization, it was kept 37 
Sample Application Buffer: 500 μl 62.5 Mm tris-HCl (pH:6.8), %2 Sodium dodecil 
oetanol, %0.01 brom phenol blue. sulphate (SDS), %20 Gliserol,  %5 β mercapt
Loading Buffer: %20 Gliserol, %0.5 Brom Phenol Blue, 60 Mm tris-HCl (pH 6.8).  
10X Running Buffer: 72.1 gr Glycine, 15 gr Tris, 5 gr SDS pH is adjusted to 8.3 and 
 When it is going to be used, it 
is diluted 10 times after it reaches the room temperature. 
Transfer Buffer:
it completed to 500 ml with dH2O and stored at 4 °C.
 Tris base 0.592 gr, Glycine 0.293 gr, SDS (%10) 337 ml, 20 ml 
2  Methanol ddH O to 100 ml. pH is adjusted to 9.2 with KOH.
Staining Buffer: %25 Ethyl Alchol, %10 Acetic Acid, %0.2 Coomassie Blue R-250, 
%65 dH2O. 
Destaining Buffer: %25 Ethyl Alchol, %10 Acetic Acid, % 65 dH2O. 
Silver Staining: Fixative solution (%50 Methanol, %12 Acetic Acid, %37 
ver 
de. 
Formaldehyde),  %50 Ethyl Alchol, 0.2 gr/L Sodium Thiosulphate, 0.2 gr/L Sil
Nitrate, %37 Formaldehy
Developer buffer: (60 gr/L Sodium Carbonate, %37 Formaldehyde, 4 mg/L Sodium 
Stop buffer
Thiosulphate.  
: % 50 Methanol, %12 Acetic Acid, % 38 dH2O.  
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6.2.2 Medium Preparations 
Growing Medium: For myeloma cells (F0) and produced hybrid cells from this F0 
ified Eagle Medium (DMEM-Gibco), %20 Fetal Calf cells, %80 Dulbecco’s Mod
Serum (FCS), Gentamisin (50 μg/ml). Strored at +4°C. 
Selective Medium: A-) It is prepared via adding Hypoxanthine aminopterin 
ored at -20°C. thymidine (50X HAT) to Normal Medium 20 ml per 1 litre and st
B-) It is prepared via adding Hypoxanthine-thymidine (50X HT) to Normal Medium 
20 ml per 1 litre and stored at +4°C. 
Freezing  Medium: It is prepared via adding %20 FCS, %80 DMEM, %10 DMSO 
(Dimethyl Sulphoxide). Lastly, DMSO is added during the freezing of the cell. 
Dulbeco’s Modified Eagle’s Medium (DMEM): 13.4 gr DMEM, 2gr NaHCO3, 5.96 
gr Hepes, %1 Sodium pyruvate are adjusted  to pH 7.2, then filtered among 0.2 μM 
to obtain sterilization. It can be stored for 6 weeks. 
Polyethylen glycol (PEG): 10 gr PEG (M.W 4000 dalton) is dissolved in 10 ml  PBS 
then autoclaved. %50 PEG for 1 ml solution can be stored in sterile tubes at room 
temperature. 
Preparation of Sodium citrate: 2.3 gr Sodium citrate, 0.8 gr Citric Acid, 2.2 gr 
a studies, different cell lines were used. This cell lines are shown in     
Table 6.1.  
Glucose are dissolved in 100 ml dH2O. For longer storage, it is kept at -20°C. 
6.3 Cells and Antigens  
In hybridom
Table  6.1 : Cell lines that were used during the study. 
CELL SOURCE 
Myeloma F0 ATCC CRL 1646 
Feeding Cell Cells from Peritoneum BALB/c mouse 
Fluid 
Cells from Spleen All lymphosite BALB/c mouse spleen 
Cells from Lymph All lymphosite BALB/c mouse lymph 
node 
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Hepatitis B core antigens were commercially bought from Fitzgerald (cat.no.:30-
Hepatitis B core Antigen Data 
AH39). The features of the antigens that  were used are shown in Table 6.2. 
Table  6.2: The features of the antigens that were used during the study. 
Grade Recombinant-highly pure 
Purity >95% by SDS-PAGE 
Source Produced in Pichia pastoris (183 amino acids) 
Concentration 1.5 mg/ml 
Form Frozen liquid in 0.02M potassium phosphate, pH 6.0 
Biohazard Not hazardous 
Storage -70°C 
Molecular weight 24 Kilodalton  
 
The antigen profile was tested with Silver staining. The result is shown in Figure 6.3. 
 
  Hepatitis B core Antigen profile in electrophoresis 
 
 
 
 
        Figure 6.3:
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MICE and RABBIT 
Immunization of mice was started with 6-8 weeks old Balb/c mice. Immunization of 
6.4 METHODS 
6.4.1 Immunization of
6-8 weeks old BALB/ mmunization 
protocol refers to type, structure and molecular weight of the antigen. Immunization 
w lied at least 3 o own in 
T
Table  6.3: gen that were used in immunization of  
m
Injection Area Maximum Antigen Type Comment 
rabbit was started with 3 months old New Zeland rabbit. 
 Mice 
c mice species were used for immunization. I
as app r 4 times. Mouse injection amount and methods are sh
able 6.3. 
 Amount  and
ice  
  type of injection of anti
Amount 
Intraperitoneal 50-500 μl Soluble or 
insoluble protein 
Easy injection 
Intramuscular 50-200 μl Soluble or 
insoluble protein 
Slow diffusion 
of antigen 
 
Intradermal 
 
50-400 μl 
Soluble or 
insoluble protein 
Difficult imm. 
Slow diffusion 
of  antigen 
Intravenous 10-100 μl Soluble protein Not efficient for 
1st 
immunization 
 
Immunization with Hepatitis B core antigen was started with 8 weeks old BALB/c 
female mice from Animal Experimentation Laboratory (Fig 6.4). For the first 
tion with Freud’s 
omplete Adjuvant (FCA) and for the second and third immunizations Freud’s 
complete Adjuvant (IFA) was used. Immunization dates for HBcAg are given 
elow on the Table 6.4. 
 
immunization antigen (2 μg/ml) was given as intraperitoneal injec
C
In
b
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Table  6.4: Mice immunization types and dates  
 
Immunization Types Immunization dates 
1.Immunization ( FCA) 27 / 12 / 2006 
2.Immunization (IFA) 10 / 01 / 2007 
3.Immunization (IFA) 30 / 01 / 2007 
 
se and antibody response against HBcAg.  
 by indirect ELISA test. 4 days before the fusion as a last reminder, antigen 
was i us, i  and f the  a half 
dose of the immunization do t using adjuvants. 
 
For the negative control mice, PBS and aduvant were mixed in 1:1 ratio and injected 
into the mouse. All injections were given to mice as a solution of approximately 200 
μl. After the second immunization, blood was taken from the mice’s tails for 
detecting the efficiency of antigen do
The most effective antibody response giving among the mice was selected for the 
fusion
njected intraveno ntraperitonal
se withou
 hand-foot pad o  mouse with
 
Figure 6.4: BALB/c mice from TUBITAK-MAM Animal Experimentation Laboratory 
unizated by Hepatitis B core Antigen with an  amount of 8 
μg/ml via subcutaneous and intramuscular injection for this purpose. The 
immunization dates are given below in Table 6.5. 
6.4.2 Immunization of Rabbit  
Immunization of rabbit with Hepatitis B core antigen was started with 3 months old 
New Zeland rabbit from Animal Experimentation Laboratory (Fig 6.5). Main aim is 
to get polyclonal antibodies for using in capture ELISA test system as a detection 
marker. Rabbit was imm
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Table  6.5: Rabbit immunization types and dates 
Im g munization with HBcA Date 
1.Immunization ( FCA) 07 / 03 / 2007 
2.Immunization (IFA) 28 / 03 / 2007 
3.Immunization (IFA) 24/ 04 / 2007 
  
fter the third immunization, blood was taken from the rabbit. Then, the effective 
inity 
A
antibody response against HBcAg was detected by ELISA test and after getting the 
effective response, serum was separated from the blood cells by centrifugation. Then, 
ammonium sulphate precipitation was applied for precipitating the immuglobulin in 
the serum. After the precipitation step, dialysis and protein A immune aff
chromatography, IgG based antibodies were obtained. Obtained antibodies are 
concentrated with ultrafiltration method and stored at 4oC. 
 
 
 
K-MAM Animal Experimentation Laboratory. 
ining animal’s immune response. Mice and 
rabbit which were imm
indirect-ELISA method [59].     
6.4.3.1 Indirect ELISA Method 
Figure 6.5: New Zeland Rabbit from TUBITA
6.4.3 Immune Response Control  
ELISA method was used for determ
unized by HBcAg, their immune response were checked with 
1- 96 well ELISA plates are coated with 100 μl antigen solution. (Antigen amount 
for HBcAg; 0.1 μg/μl). ELISA plates are incubated for at least 6 hours or over night 
at 4°C.  
2- Plates are washed 3 times with PBS-Tween 20. 
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3- Plates are coated with %0.2, 200 μl BSA solution for blocking. It is incubated 1 
hour at
4- Plates BS-Tween 20. 
5- Each h r mice sera is added and incubated at 37 °C for 1 
hour. Supernatants of the hybridomas are taken with micr oated with an 
ount of 100 μl directly to the plate. Mice serums are diluted with PBS. 
d at 405 nm by ELISA 
eader. 
6.4.4 Separation of HBc antigen with PolyAcrylamide Gel Electrophoresis 
%10 SDS- PAGE: 4 ml H2O, 3.3 ml %30 acrylamide, 2.5 ml 1.5 Tris-HCl (pH 8.8) , 
0.1 ml %10 sodium dodecyl sulphate, 0.1 ml %10 ammonium persulphate (APS), 
0.004 ml tetramethyl etilen diamine (TEMED) were mixed to prepare resolving gel 
and with the help of pipette this mixture was given to the apparatus. Then,on to the 
top of the gel butanol was added drop by drop. After the gel was freezed, butanol 
 and 
poured on the resolving gel. The way of preparing stacking gel is, 3.4 ml dH20, 0.83 
l 1.0 M Tris (pH 6.8), 0.05 ml %10 SDS, 0.05 
o PAGE apparatus and 10X running buffer (with 
GE apparatus (Fig 6.6).  
 37°C. 
are washed 3 times with P
ybridoma supernatant o
opipette and c
am
6- Plates are washed 3 times with PBS-Tween 20. 
7- Wells are coated with anti-mouse-IgG or polyvalent immunoglobulins (IgG-IgA-
IgM) which joined with alkaline phosphotase. Before this solution is coated on 
plates, it is diluted 1/1000 with PBS and incubated 1 hour at 37°C .  
8- Plates are washed 5 times with PBS-Tween 20. 
9- After the washing step, substrate buffer is added and incubated for 45 minuted  in 
the dark at room temperature. Antibody level is detecte
R
was removed with the help of blotting paper. Then, stacking gel was prepared
ml %30 acrylamide solution, 0.63 m
%10 APS, 0.005 ml TEMED.  
While waiting for the gel to freeze, combs were put into gel to form wells. After the 
gel was freezed, it was put int
diluted to 1X) was added on to PA
Sample  Preparation: Before loading the antigen samples to the PAGE apparatus, 
they were mixed with loading buffer 2X, then heated at 95oC for 3 minutes. If 
particulate was present, samples were centifugated for 30 minutes at 14K RPM in a 
l. Simultaneously, marker protein 
as loaded directly to the gel apparatus. 
microcentrifuge, and they were loaded on to the ge
w
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 Figure 6.6: SDS-PAGE Apparatus from GMBE Laboratories 
 the gel’s protein bands were made visible by using destaining buffer.  
to the hemocytometre, cells were counted as the 
number of cells per 25 square. The formula of cell number computation is given 
umber           
6.4.4.1 Staining of Antigenic Determinant with Coomassie Blue 
After the SDS-PAGE section, gel was exposed to staining buffer over night. In the 
morning,
6.5 Cell Culture Studies 
6.5.1 Transferring Cells from Liquid Nitrogen to Culture Flasks  
Cells which had been stored in (-196°C) liquid nitrogen were thawed in 37°C 
waterbath and taken into PBS buffer for centrifugation for 10 minutes at 1100 rpm. 
Cell pellet was dissolved with DMEM medium and transferred to the culture dishes. 
6.5.2 Cell Counting  
Cell pellet was suspended and completed to 50 ml with PBS. Then, one drop of 
suspension was taken and put on
below: 
   104     X      Volume (50 ml)      X     Amount of Counted Cell   = Cell N
(constant number)   (volume that contain cells)                                                                     ( per mililiter) 
 
 
48 
 
6.5.3 Cell Passage  
Cells in culture dishes were in growing medium. Growing medium was discarded 
and 10-15 ml PBS was poured. Cells that were stuck on the culture dish, were lifted 
via cell scraper. Suspended cells were put into the centrifuge tubes at 900 rpm. After 
the centrifugation upper part was discarded, pellet was suspended with PBS and 
again centrifugated. Centrifugation step with PBS was repeated two times.  
6.5.4 Cell Freezing  
After the cell passage, cells were taken to the centrifuge tubes and they were washed 
with PBS. Whe red to freezing 
tubes with freezing medium for future applications. Estimated cell number for per 
ing Cells  
Feeder cells were prepared a day before the fusion. Unimmunized, normal mouse 
e, then it was 
 
 inner membrane. Feeding cell mixture was taken to 
ber was detected by cell counting. Desired cell number 
the mice the highest immune response giving was selected by indirect-
backside. With the scissors, left-sided skin incision was made, midway between the 
ib and the hip joint. 1 to 2 cm incision was made in the peritoneal wall and 
gently the spleen was pulled onto the exterior surface of the peritoneum. Any 
onnective tissue under the skin was annihilated using the blunt end of the forceps. 
The spleen was removed from the body. Spleen tissue was put into petri dishes 
n the washing step was finished, cell pellet was transfer
freezing tube was 3x106 cell/ml. 
6.6 Preparation for Fusion 
6.6.1 Preparation of Feed
was used. Dislocation method was applied to unimmunized mous
disinfected in %70 alcohol. Mouse was taken into laminar flow, was placed on the 
dissecting board in the dorsal position. 5 ml only DMEM was injected to the 
peritoneum of mouse and after a few minutes, DMEM was taken back with feeding
cell mixture from the peritoneum
the sterile tube and cell num
per well in cell culture plate is ~6000 cell and desired volume is 100μl for per well.  
6.6.2 Obtaining Spleen Cells from Immunized Mouse  
Among 
ELISA test and was killed by dislocation method. The mouse was sterilized with 
70% ethanol. Mouse was taken into laminar flow. The animal was laid on its 
last r
c
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containing 5 ml PBS buffer in order to purify it from the fatty tissues. Spleen tissues 
p. Spleen 
cells are shown in Figure 6.7. 
were crushed onto strainer with glass baggette. After the spleen tissues were crushed, 
they were revealed and suspensed with the help of pipette. Cells were washed 2 times 
with PBS buffer at 900 rpm for 10 minutes. Pellet was taken into 50 ml PBS buffer 
and cell number was determined by cell counting. After the cell counting, the last 
washing step was done. Cells were taken into 10 ml PBS buffer as a last ste
 
Figure 6.7: Image of Spleen Cells 
6.6.3 Obtaining Lymph Nodes from Immunized Mouse  
The highest immune response giving among the mice was selected by ELISA test 
and killed by dislocation method. Mouse was taken into laminar flow. Mouse fur was 
wetted with 70% ethanol. Incision was started from genital region to lower (inferior) 
chin. Lymph nodes, two pairs of surface lymph nodes  from chin and armpit, one pair 
le on back, were collected 
(Fig 6.8). Removed lymph nodes were taken to the petri dish and mechanical force 
on openned skin and groin, 4 granule on intestine, 3 granu
was applied to revealed lymph cells. After the suspansion, cells were counted. In this  
study, both lymph nodes and spleen tissue were collected at the same time. First, 
mouse was incised for getting the lymph nodes and after that spleen tissue was 
removed. 
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 Figure 6.8: Shematic representation of mouse lymph nodes and spleen [59]. 
6.6.4 Preparation of Myeloma Cells  
Ten days before the fusion, F0 myeloma cells were started to be cultivated in normal 
medium (Fig 6.9). Beginning of cell reproduction studies, 20 μg/ml azoguanin was 
added to the medium for rem e fusion day,  
 passage and cells were 
ove HGPRT (-) mutant cells. In th
myeloma cells were removed from the flasks by making
washed 2 times with PBS buffer while centrifugation at 900 rpm for 10 minutes. 
Pellet was taken into 50 ml PBS buffer and cell number was determined by cell 
counting. After the cell counting, the last washing step was done. Cells were taken 
into 10 ml PBS buffer as a last step. 
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 Figure 6.9: Image of F0 Myeloma cell 
6.7 Fusio
n proportion to 1/10-1/5 and centrifugated at 
ersed to the cell culture plates which 
contains feeder cells that had been prepared one day before the fusion as a final 
ount of 150 μl/well. 
6.7.1 Following the Culture After the Fusion 
Ten days after the fusion, 100 μl/well was removed from the cell culture plates and in 
place of removed medium, 100 μl/well HAT culture medium was poured.  
 
 
 
 
n 
Myeloma/lymph cells were combined i
900 rpm for 10 minutes. After the centrifugation, upper part was removed and pellet 
was taken. 1 ml Polyethylen glycol (PEG) 4000 which was heated at 37°C was added 
to the precipitated cells very slowly within 1 minutes. 4 ml only DMEM was added 
(without FCS+antibiotic) very slowly within 2 minutes. 20 ml only DMEM was 
added within 2 minutes. Finally, 20 ml DMEM that contains %15 FCS was added 
within 2 minutes. Mixture was held an hour at 37°C in CO2 incubator and taken to 
the centrifuge. After the centrifugation, pellet was suspensed with HAT culture 
medium and the formed mixture was disp
am
52 
 
In ten days period, cells have active, big and clear image and some of them can 
produce clones. Hybridoma cells are shown in Figure 6.10, 6.11, 6.12. 
 
 
 
 
 
 
 
 
                              Figure 6.10: Cell mixture immediately after fusion 
 
Figure 6.11: Cell mixture after 4 days in HAT medium 
 
Figure 6.12: Cell mixture after 10 days in HAT medium 
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6.7.2 Subcloning of Hybrid Cell (Limiting Dilution) 
Monoclonal antibodies are secreted by the progeny of a single cell that can produce 
nly a single anti
required to e avoided and the risks of 
cell cultures with g  in a mean of one 
cell per we bodies are recloned. 
t 3 times after 
 
ecipitation 
Ammonium sulphate was added over the hybrid supernatant in amount of %45 in the 
cold room in 30 minutes. Supernatant was stirred over night at 4°C. After 
centrifugation for 1 hour at 13.000 rpm at 4°C, pellet was dissolved in PBS and 
dialyzed at 4°C against PBS  over night. 
6.7.3.2 Protein-A Immune Affinity Chromatography  
Protein-A immuno-affinity column was used for antibody purification (Fig 6.13). 
Column was washed with binding buffer. After the application of the ammonium 
sulphate precipitation to the  hybrid supernatant, this solution was passed through the 
0.45 μm filter. Then, the solution was loaded to the protein-A immune affinity colon. 
Immediately, colum
buffer was added. Absorbance value of the tubes were measured in 280 nm and 
binding buffer was passed through the column until the absorbance value became 
zero. Then, elution buffer was loaded. Antibodies were collected in neutralizing 
buffer containing tubes. Solution value was measured until the absorbance value 
became zero. Column was washed with %20 ethanol which was 2 times more than 
colon’s volume and stored at 4 °C. After the application, tubes were tested with 
ELISA method and active antibodies were determined. 
o body (assuming a nonsecretory fusion-partner line). Subcloning is 
 ensure that the problems of polyspecificity ar
overgrowth by nonproducing cells are minimized. The procedure involves setting up 
raded dilutions of the cell suspension resulting
ll. Cells that are determined to give desired anti
Recloned cells are frozen and stored.  The recloning is repeated at leas
which the final clone plate should display positive antibody production [47]. 
6.7.3 Purification of  Monoclonal Antibody 
6.7.3.1 Ammonium sulphate pr
n zone section was collected in 1 ml tubes, and then binding 
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 Figure 6.13: General llustration of Affinity Chromatograhpy Method [55] 
 are used. There are several methods for 
6.7.4 Large Scale Production of Hybridomas 
Hybrids are transferred to the different sized culture flasks to have high amounts of 
antibody yield. For that reason, 75 cm2 one folded, 150 cm2 one/three folded and 500 
ml culture flasks with magnetic shaker
production of hybridomas on a large scale. 
6.7.4.1 Large Scale Production in vitro  
In this process 75 cm2 and 150 cm2 culture flasks are used. Furthermore, small 
spheres which are coated with polystyrene material, can be put into magnetic stirrer 
culture flask. This small spheres are useful for cells to stick on and to spread growing 
antibodies in the  culture medium so that enough antibodies can be collected (Fig 
6.14). Cell culture supernatant has approximately 10-50 μl monoclonal antibody per 
1 ml [60]. 
 
Figure 6.14:  Magnetic-stirrer culture flasks for production of large scale antibodies [51] 
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6.7.4.2 Large Scale Production in vivo 
BALB/c mice is used for this method. In this method, actively multiplying hybrid 
cells are either put under the BALB/c mice skin or in the abdomen with an amount of 
1.106 cell/ml. Two weeks before starting this process, pristane (tetramethyl penta 
decone) is given to mice in an amount of 0.5 ml. Pristanes function by accelerating 
tumor formation and, by weakening the mice’s immune system. Hence, when 
hybridomas are given to mice body, ascites will be formed in 2-4 weeks time in the 
mice abdomen. Formed liquid is taken by syringe. Amount of monoclonal antibody  
can be 10-50 mg per 1 ml. 
Antibodies either from culture supenatant or abdomen were centrifugated and 
separated from other cells. Antibodies can be stored at -20°C for one year,  in storage 
buffer for ity of the 6 months. Freezing and defrost of antibodies can effect the activ
antibodies. 
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7. RESULTS 
7.1 Mice Results 
After mice second immunization with Hepatitis B core antigen, 4 mice immune 
response were checked with indirect ELISA method (Fig. 7.1). 
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Figure 7.1: Mice’s serums were diluted in proportion to 1/400 with PBS for measuring their 
immune response.  
Antibody response was measured from immunized mice blood serum. This serum 
was collected from tail vein of the mice. The blood was collected in a microfuge tube 
containing sodium citrate. Tubes were centrifuged at 6000 rpm/1min to remove the 
blood cells. The plasma samples were tested by indirect-ELISA test system. Plasma 
from an unimmunized mouse in PBS was used as a negative control. A mouse 
responsive to immunization against HBc antigen was selected as spleen donor for the 
fusion. The first fusion experiment was started with right-left ear marked mouse. 
Fusion studies were carried on with two separate fusion study. One of them was 
spleen fusion, the other one was lymph node fusion. 
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7.1.1 Optimization of Antigen Usage with ELISA Method 
In fusion studies, high amount of core antigen will be used for detecting hibrid cell 
antibody activity. Because of core antigen expensiveness, optimization of antigen 
 determined. For determining the optimum antigen usage, ELISA 
plates were coated with various amount of core antigen and by using active mouse 
le amount was determined for ELISA tests. 20 ng was found as 
the most suitable antigen amount for antigen usage for ELISA tests. The result is 
usage must be
plasma most suitab
shown in Figure 7.2. 
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Figure 7.2: Right-left ear marked mouse’s serum is tested for detecting optimum antigen usage for 
experiments. ELISA plate is coated with 10 ng, 20 ng, 40 ng and 80 ng amount of HBcAg.  
The first fusion results of right-left ear marked mouse which was immunized with 
HBcAg are summarized in Table 7.1 
Table 7.1: The first fusion results of right-left ear marked mouse which is immunized with 
HBcAg. 
 
Number of Cell 
Spleen Fusion        Lymph Node Fusion*
  225 x  10   6                                                -
Number of F0 myeloma cell      90 x  106                                                 -
Total Number of  Studied Well        1400                                     -           
Total Number of Hybrid Cell         234                                      - 
Number of Antibody Producer 
Hybrid cell 
      1 (6C2)                                  - 
Specific Antibody Producer Hybrid 
Cell Against HBcAg 
          -                                         -  
Lymph Node Fusion*: This fusion could not be applied because of cell’s stickiness and not 
enough suspension. 
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According to given information above, only one hybrid cell showed activity in 
m albumin. 
Antigen 
ELISA test. Antibody activity was decreased day by day, probably one of the reason 
can be chromosome loss in the hybrid line secreting antibodies. In the last cross 
reaction tests results, the decrease of antibody activity can be seen in Table 7.2. 
There was not any specific hybrid cell produced against HBV core antigen. 
Table  7.2: Cross reaction test results with other antigens in the first fusion study. HBcAg: 
hepatitis c antigen; HBsAg: hepatitis surface antigen; HBeAg: hepatitis e antigen; HSA; 
Human Serum Albumin; BSA: Bovine seru
Hybrid Cell 
HBcAg HBsAg HBeAg Human Serum      BSA           6C2 
0,128 0,163 0,126 0,175 0,121 
According to first fusion results, forth immunization (2 μg/ml+ IFA per mouse) with 
HBV core antigen was applied to mice to increase the immune response for 
following fusion studies. One week after the 4th immunization immune response was 
checked with ELISA test. In respect of this graphic, right-ear marked mouse was 
chosen for second fusion study (Fig 7.3).  
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Figure 7.3: Mice’s serums are diluted in proportion to 1/40 eir immune 
re
 
 
 
 
 
0 with PBS for measuring th
sponse with indirect ELISA test.  
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Results for the 2nd fusion study is given below in Table 7.3. 
Table  7.3: The detail of Second Fusion 
 
 
  
Number of Cell 
Spleen Fusion      Lymph N.Fusion 
 
6         300x10    135 x 106
Number of F0 myeloma cell          60 x 106   45 x 106
Total Number of  Studied Well 768      672 
Total Number of Hybrid Cell 918                   33 
Number of Antib duce d 
cell 
 ody Pro r Hybri 18       - 
Specific Antibody Producer Hybrid Cell 
Against HBcAg 
                -                                    - 
 
In fusion culture, 18 hybridoma cells which gave high antibody activity showed low 
antibody activity at their repeated ELISA test. These antibodies were also tested for 
cross-reaction with the other antigens. 1:1000 dilution of conjugate was used in 
ELISA test. Decreased antibody activity can be seen in Table 7.4. 
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Table  7.4: Comparison of the reactivity (OD405) of the monoclonal antibodies (2C7, 5D8) 
s core antigen; HBsAg: hepatitis surface antigen; 
 Serum Albumin; BSA: Bovine serum albumin 
Hybrid 
Cells Antigen  
with different antigens. HBcAg: hepatiti
HBeAg: hepatitis e antigen; HSA: Human
 
 HBcAg 
 
 
HBsAg HBeAg Huma  serum
n
 BSA 
2C7 0,295 0,343 0,35 0,40 3 5 9 
 
0,39
 
5D8 0,507 0,435 0,38 0,572
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9  0,4
 
Because of insufficient results in the monoclonal antibody production against HBV 
ore antigen, third fusion studies were done with the left-ear marked mouse. Mice c
immune results is shown in the Figure 7.4. Fusion results are shown in Table 7.5. 
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Figure 7.4: Left ear marked mouse taken to the third fusion study. Mice’s serums are diluted in 
proportion to 1/200 with PBS for measuring their immune response with indirect ELISA test.  
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Table 7.5: Third fusion results for immunized mouse with HBV-core antigen 
N  Cell 
 
 
  Spleen Fusion     Lymph N. Fusion 
        275 x10    35 x 106 6
umber of
Nu f F0 myeloma Cell          90 x 106   20 x 106mber o
Total Number of  Studied We 6     ll 86  672 
Total Number of Hybrid Cell 10                    3
Num of An  Produ ybrid 
Cell 
 -    ber tibody cer H     - 
Specific Antibody Producer Hybrid Cell 
Against HBcAg 
  -                                                 - 
 
Because of not getting effective results for the first four fusion tests, new fusion 
studies with new mice series were started. Applied the same procedure for the 
immunization of mice. Fourth fusion study was started with unmarked immunized 
mouse according to Figure 7.5. Fourth fusion result is shown in Table 7.6. 
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Figure 7.5:
in
 Fourth fusion study is started with unmarked marked mouse. Mice’s serums are diluted 
 proportion to 1/1600 with PBS, measured their immune response in 60 minutes at OD405nm with 
indirect ELISA. 
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Table 7.6 Fourth  fusion results for immunized unmarked mouse with HBVcore antigen 
  S 
 
Number of Cell 
pleen Fusion        Lymph N. Fusion 
 
         250x106   50 x 106
Number of F0 myeloma Cell     20      95 x 106   x 106
Total Number of  Studied Well 8     64  576 
Total Number of Hybrid Cell 2    07                1 
Number of Antibody Producer Hybrid 
Cell 
4        - 
Specific Antibody Producer Hybrid Cell 
Against HBcAg 
                -                                      - 
 
Before starting the fifth fusion study, non immunized mouse feeder cells were 
dispersed to 7 piece of fusion plate and the other 7 fusion plate were subjected to 
immunized mouse feeder cell. Different from the preceding fusions, spleen and 
lymph nodes of the mouse were fused in the same ependorf tube. Following 
procedure was similar with the former fusion studies. Fifth fusion result and mice 
immune response are shown in Figure 7.6 and Table 7.7 respectively.  
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F
p
igure 7.6: Fifth fusion study is started with left-ear marked mouse. Mice’s serums are diluted in 
roportion to 1/1600 with PBS, measured their immune response in 60 min at OD405nm with 
rect-ELISA. 
 
 
indi
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Table 7.7: Fifth  fusion results for immunized left-ear marked mouse with HBV-core 
antigen 
Fusion Spleen and Lymph 
Mix Fusion 
Total Number of Lymphocyte Cell  20 x15 06; 
Number of F0 Cell (FO ATCC CRL 164 22 x 6) 1 106
Total Number of  Studied Well 1144 
Total Number of Hybrid Cell 693 
Number of Antibody Producer Hybrid Cell 27 
Specific Antibody Producer Hybrid Cell Against 1(12C9) 
HBcAg 
 
ntibody producer hybrid cells are obtained. For this assay, 
Table 7.8: Comparison of the reactivity (OD405) of the 12C9 hybrid cell with hepatitis 
antigens and proteins. HBcAg: hepatitis core antigen; HBsAg: hepatitis surface antigen; 
HBeAg hepatitis e antigen; HSA; HumanSerum Albumin; BSA: Bovine serum albumin 
Hybrid 
Cell Antigen 
In this fifth fusion, 27 a
antibody producer hybrid cell supernatants were tested for antibody activity for 
HBcAg. These antibodies were also tested for cross reaction test to identify their 
specifity with other antigens and proteins. Only one of them showed high specificity 
against HBcAg, 12C9, at the same time it did not show any cross reaction with other 
antigens and proteins (Table 7.8).  
HBcAg HBsAg HBeAg Human Serum  BSA Transferin       12C9 
1.892 0.149 0.123 0.186 0.155 0.168 
 
To identify antibody subtype, hybridoma subisotyping kit system was used. 
Monoclonal antibody (12C9) subtype was found to be IgM subtype. In addition, this 
contained kappa light chains (Fig 7.6). 
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Figure 7.7: Immunoglobulin class of monoclonal antibody (12C9) 
atant was harvested for purification.  
The protocol involved centrifugation of monoclonal antibody supernatant, followed 
ine 
ser ize- exclusion (SE) chromatography. The purity of IgM is checked by 
SDS-PAGE and e IgM ed in ffer [
7.2 Rabbit Resu
marker in patient serum. Rabbit Polyclonal 
anti-HBcAg immune results are shown in Figure 7.8. 
12C9 hybrid clone producing antibody with the highest specifity was subcloned by 
limiting dilution. At each stage of growth, aliquots of hybrid cultures (3-5.106 cells) 
were frozen in liquid nitrogen in freezing medium. To have large quantities of 12C9 
supernatant, cells were grown in smaller flasks, then gradually were expanded into 
large volume roller flasks. The supern
by simple dialysis against water. IgM type antibody was separated from 
contaminating proteins such as normal mouse proteins or proteins from fetal bov
um by s
 the pur  is stor  PBS bu 55]. 
lt 
The rabbit was immunized with HBVcore antigen for producing polyclonal 
antibodies. As a future aspect, polyclonal antibodies will be used in capture ELISA 
test systems as an antibody detection 
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Rabbit HBcAg Dilution Test
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Figure 7.8: Rabbit Polyclonal anti-HBcAg Dilution Test for testing the immune response aft  the 
third immunizat
rafiltreted 
via tulip-shaped glasses for getting more concentrated sample. In 7.9 numbered 
er
ion. 
After getting strong immune response from the rabbit, approximately 20 ml blood 
was collected and the blood clot was separated from the serum by centrifugation. 
During the elution step in protein A immunaffinity chromatography, antibody 
activity among the collecting solution tubes were detected by  measuring the samples 
with the spectrophotometer at OD280. Relevant tubes were picked and ult
figure, there is a spectrophotometric result during the affinity chramotography and 
after the ELISA test for the same serum samples. Preimmune serum from the same 
animal is used as a negative control in ELISA test. 
HBcAg Polyclonal Rabbit MAb-Trap Results
2,5
29 31
Tube Number
0
1,5
2
2
0
0,5
1
1,5
1 3 5 7 9 11 13 15 17 19 21 23 25 27
O
D
28
0n
m
0,5
1
O
D
40
5n
m
OD 280
OD 405
 
 Figure 7.9: Purification of monospecific anti-HBc polyclonal antibody by using protein A 
immuno-affinity chromatography. 
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Samples were measured at OD 280 and according to these results, related samples 
which have high absorbance values, was tested indirect-ELISA (OD405). Positive 
antibody samples were pooled (23-31 tubes) and were concentrated by ultrafiltration 
unit. Concentrated samples were stored at 4oC for future usage. 
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8. DISCUSSION 
he genesis of monoclonal antibodies was the work of Georges Kohler and Cesar 
ilstein at Cambridge University in the 1970s. They fused a single antibody 
roducing cell  from the spleen of an immunized mouse with a mouse myeloma cell 
 produce an immortal hybrid cell that secreted an antibody to a single antigenic 
pitope. The fusion is mediated by Sendai Virus. At the end of the fusion process, the 
ntibody producing spleen cell provided the specificity and the myeloma cell 
rovided the immortality [61]. This antibody producing hybrid cell could be 
erpetuated indefinitely in tissue culture. Their report in the 7 August 1975 issue of 
ature (256:495-7) entitled “Continuous cultures of fused cells secreting antibody of 
redefined specificity” led to the Nobel Prize in Medicine in 1984.  Since the Nobel 
rice winning work of these researchers, MAbs have become essential tools in basic 
search as well as in diagnostic testing and medical treatments.  
ince then, approximately 300 development programmes for therapeutic antibodies 
ave been reported in industrial and academic laboratories and this clearly 
demonstrates the commitment of the contemporary pharmaceutical industry to 
discovery and clinical development of medicines that are complex macromolecules. 
Fortunately, the technological revolution in antibody engineering has occurred 
concurrently with an expanded understanding of cell biology and pathology at the 
molecular level through genomic and proteomic research along with improved 
cellular and animal models. Marketed monoclonal antibodies target well investigated 
proteins. Moreover, antibodies are used in several diagnostic tests to detect small 
amounts of drugs, toxins or hormones, For example, monoclonal antibodies to 
human chorionic gonadotropin (HCG) are used in pregnancy test kits, Another 
diagnostic uses of antibodies is the diagnosis of Hepatitis B by the ELISA test [62]. 
In Turkey, Hepatitis B diagnostic kit systems are imported from other countries. The 
use of imported diagnostic kits causes economical dependency and important 
economical losses because of its high cost. For this purpose, diagnostic systems 
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based on the use of monoclonal antibodies will be developed for early and sensitive 
iagnosis of Hepatitis B in TUBiTAK’s project.  
he process of MAb development includes the following successive working phases: 
e generation of antigen specific B cells, the fusion of these cells with myeloma 
nd selection of the specific hybridoma clone by “limiting dilution” 
and the up-scaling of MAb production [63]. 
rive immortality by 
d
T
th
cells, the cloning a
Critical aspects that should be considered while producing antibodies include antigen 
selection, aseptic antigen processing, adjuvant selection, preparation of antigen 
adjuvant mixture, choice of immunization route and injection volume. In this study, 
Hepatitis B core antigen was bought commercially from  Fitzgerald. Immunizations 
were applied by intraperitoneal and intravenous routes. Immunizations were repeated 
for several times. Booster and first  immunization of antigen were done with Freud’s 
complete adjuvant to provoke the immune response more effectively, but the last 
immunization was done with incomplete adjuvant. 
To produce MAb, antibody secreting B cells were immortalized by the fusion of the 
host immune B cells with a nonsecretory myeloma cell line. Since the unfused 
normal B cells cannot survive long in an in vitro culture, they de
fusion to a partner tumor cell line. If a hybridoma that produces the antibody of 
interest was identified and subjected to a cloning procedure that results in 
monoclonality, a MAb of desired specificity is produced.  
In the study,  ATCC CRL 1646, F0 cell line is used which is bought commercially. 
With this myeloma cell line, 5 fusion study was carried on and different fusion 
experiments are still continuing. At the fifth fusion study, one specific hybrid was 
found against HBcAg. 12C9 named hybrid was not give any cross reaction with 
other proteins. This result brings a conclusion that 12C9 named hybrid is producing 
specific antibody against HBcAg.  
Afterwards, for having large quantities of 12C9 supernatant, cells were first grown in 
smaller flasks, and then gradually expanded into large volume roller flasks. The 
supernatant was harvested for purification step with size exclusion (SE) 
chromatography and a little amount was stored in aliquates in liquid nitrogen. At the 
same time, in order to reduce antibody producing cell mass into one cell, limiting 
dilution method was used. Continued growth of this clone will result in a long-term 
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dependable source of monoclonal antibodies. The produced monoclonal antibodies 
were detected as IgM type instead of IgG type. It is common to come across with this 
 synthesis of antibody. However, this 
response can be mitigated by binding of antigen to carriers or by immunizing the 
 carrier protein to provoke the 
immune response.  
an be obtained at each bleed from the rabbit. The 
result.  This is because, antigen which enters the body, does not stimulate T cells and 
macrophages instead it stimulates B cells directly. Furthermore, antigen which 
choses thymus independent stimulation, has a lot of same epitopes that genetic 
modification of antigen is directed to IgM
animal with an adjuvant. 
Stable immune activity did not obtain during the first fusion studies. This can be 
caused by small molecular size of the antigen. Hepatitis B core antigen is 
approximately 24 kilodalton. Different mice could show different immune response 
against the antigen. During the first fusion studies because of not getting effective 
response could be caused by this effect. For future fusion studies to eliminate this 
situation, hepatitis B core antigen would bind to
The other work in this study is production of polyclonal antibodies against Hepatitis 
B core Antigen. Polyclonal antibodies are produced by a mixture of various B 
lymphocyte clones. In making a choice between producing PAbs or MAbs, the 
desired application of the antibody and the time and money available for production 
should be considered. 
Choice of species is relevant, particularly when producing polyclonal antibodies  
because the quantity of antibody harvested is dependent on animal size. Rabbits are 
most frequently used to generate antibodies for research because they are easier and 
less expensive to house. 
In the study, New Zealand rabbit type was used for producing polyclonal antibody, 
since 30 to 50 ml of whole blood c
life span of a rabbit is 5 to 6 years, hence a continual source of specific antiserum can 
be provided over a period of time by one rabbit after booster injections. 
Rabbit was immunized 3 times in an amout of 8 μg/ml with Hepatitis B core 
Antigen. Freund’s Complate Adjuvant (CFA) was used for the first immunization.  
Because it induces a high, long-lasting antibody titer that is often still measurable at 
25 weeks or more after boosting. The presence of mycobacteria in CFA activates the 
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T cell population, providing necessary lymphokines for B cell stimulation and 
maturation [64]. At the end of each immunization period, immune response of rabbit 
was checked with indirect ELISA method. More diluted antibody showed more 
antigen binding activity. According to Figure 7.8, the optimum antibody response of 
rabbit was detected at 1/600 dilution after the third immunization. Higher titer of 
specific antibody was achieved and sustained for a longer period of time by 
harvesting the blood of the rabbit.  
Blood was collected between 7 and 14 days after the each booster to ensure high 
y, size-exclusion (SE) chromatography will be applied to obtain 
re aspects, it will used in capture based test kits for detecting 
 
titer. Approximately, 20 ml of antiserum was collected, and ammonium sulphate 
precipitation was applied to precipitate proteins. The precipitate was recovered by 
centrifugation and dissolved in PBS, then dialyzed and purified by protein A affinity 
chromatography. Relevant tubes were picked after the chromatography and 
ultrafiltreted via tulip-shaped glasses for getting concentrated sample. 
Both monoclonal antibody and polyclonal antibody were produced in this study. For 
monoclonal antibod
pure IgM antibodies and as a future aspect it will used in competitive based test kits 
for detecting Hepatitis B antibody in patient’s serum. But, antibody usage in kit 
systems requires optimization by comparing with different ELISA tests and 
determination of the antibody specifity. For polyclonal antibody, it was purified and 
stored at 4Co. As a futu
Hepatitis B antibody in patient’s serum. Moreover for optimization of this kit system, 
it requires enzyme (Horseradish Peroxidase) labelling to antibody and optimization 
of antibody usage for kit systmes. 
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